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Review article
Awareness and willingness to use HIV pre-exposure
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Abstract
Introduction: To facilitate provision of pre-exposure prophylaxis (PrEP) in low- and middle-income countries (LMIC), a better
understanding of potential demand and user preferences is required. This review assessed awareness and willingness to use
oral PrEP among men who have sex with men (MSM) in LMIC.
Methods: Electronic literature search of Cochrane library, Embase, PubMed, PsychINFO, CINHAL, Web of Science, and Google
Scholar was conducted between July and September 2016. Reference lists of relevant studies were searched, and three
authors contacted for additional data. Non-peer reviewed publications were excluded. Studies were screened for inclusion,
and relevant data abstracted, assessed for bias, and synthesized.
Results: In total, 2186 records were identified, of which 23 studies involving 14,040 MSM from LMIC were included. The
proportion of MSM who were aware of PrEP was low at 29.7% (95% CI: 16.9–44.3). However, the proportion willing to use
PrEP was higher, at 64.4% (95% CI: 53.3–74.8). Proportions of MSM aware of PrEP was <50% in 11 studies and 50–70% in 3
studies, while willingness to use PrEP was <50% in 6 studies, 50–70% in 9 studies, and over 80% in 5 studies. Several factors
affected willingness to use PrEP. At the individual domain, poor knowledge of PrEP, doubts about its effectiveness, fear of
side effects, low perception of HIV risk, and the need to adhere or take medicines frequently reduced willingness to use PrEP,
while PrEP education and motivation to maintain good health were facilitators of potential use. Demographic factors
(education, age, and migration) influenced both awareness and willingness to use PrEP, but their effects were not consistent
across studies. At the social domain, anticipated stigma from peers, partners, and family members related to sexual
orientation, PrEP, or HIV status were barriers to potential use of PrEP, while partner, peer, and family support were
facilitators of potential use. At the structural domain, concerns regarding attitudes of healthcare providers, quality assurance,
data protection, and cost were determinants of potential use.
Conclusions: This review found that despite low levels of awareness of PrEP, MSM in LMIC are willing to use it if they are
supported appropriately to deal with a range of individual, social, and structural barriers.
Keywords: HIV; pre-exposure prophylaxis (PrEP); men who have sex with men (MSM); low and middle income countries;
systematic review
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Introduction
Human immunodeficiency virus (HIV) is a leading cause of
the global burden of disease [1] and mortality [2].
Currently, 36.7 million people are living with HIV globally,
and on average, 1.1 million people die from it annually [3].
Although significant progress has been made in increasing
access to antiretroviral therapy [2,3], world-wide incidence
of HIV has remained above two million cases annually over
the last decade [3], suggesting that additional HIV preven-
tion interventions are required.
HIV pre-exposure prophylaxis (PrEP) is the provision of anti-
retroviral (ARV) drugs to HIV-uninfected people at high risk
before potential exposure, to block the acquisition of HIV
[4,5]. In randomized clinical trials (RCTs) conducted in high-,
middle-, and low-income countries, PrEP reduced the risk of
HIV acquisition by 44% among men who have sex with men
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(MSM) and transgender (TG) populations [6], 48% among peo-
ple who inject drugs [7], and 67% among heterosexual serodis-
cordant couples [8]. In recent RCTs conducted in the UK and
France, PrEP reduced the risk of HIV acquisition by 86% among
MSM [9,10]. In all these studies and their open-label exten-
sions, significantly higher levels of protection from HIV were
experienced by participants who were adherent to PrEP [11].
The World Health Organization (WHO) recommended the
use of daily oral PrEP to reduce HIV acquisition by HIV-
negative partners within serodiscordant heterosexual cou-
ples in 2012 [4]. In 2015, WHO expanded the recommenda-
tion to include MSM and people who inject drugs [5]. WHO
recommends PrEP to be used as part of a package of
combination prevention interventions [5] that includes HIV
testing, condom use, as well as screening and treatment of
sexually transmitted infections (STIs) [4].
Following these recommendations, studies [12,13] and
reviews [14,15] exploring awareness, willingness to use, and
acceptability of PrEP among MSM have started to emerge
over the last few years. However, these recent reviews have
been broad in scope, and have included data from high-
income countries. In his review, Holt [14] focused on accept-
ability of PrEP and use of ARV treatment as prevention among
MSM in the Americas and Asia pacific, while Young and
McDaid [15] focused on global acceptability of PrEP among
all populations. While both reviews found that PrEP and
treatment as prevention are reasonably acceptable, the
over-representation of studies from high-income countries in
both reviews, as well as the mixed populations in Young and
McDaid’s review [15], limits the extent to which the findings
may be applicable to MSM in low- and middle-income coun-
ties, where implementation of PrEP has been relatively limited
compared to high-income countries [15,16].
In addition, Young and McDaid’s review [15] highlighted an
urgent need to better understandmotivations for willingness to
use PrEP beyond clinical trials. Such information will inform
practical ways in which MSM and other potential users can be
best supported to access andutilize PrEP, particularly in low-and
middle-income countrieswhere experiencewith PrEP is limited.
To respond to these information needs, we sought to examine
the awareness of and factors associated with willingness to use
oral PrEP among MSM in low-and middle-income countries.
Methods
This review was conducted in accordance with the pre-
ferred reporting items for systematic review and meta-
analyses [17] and protocols [18]. The protocol was regis-
tered in PROSPERO (ID: CRD42016043994) and the PRISMA
checklist is appended as supplemental file 1.
Search strategy
Between July and September 2016, a search was conducted
in Cochrane library, Embase, PubMed, PsychINFO, CINHAL,
Web of Science, and Google Scholar to identify relevant
peer-reviewed articles related to awareness and willingness
to use PrEP among MSM in low-and middle-income coun-
tries. Non-peer reviewed literature was not included. The
search string utilized a combination of relevant keywords
and was adapted for use with each database, using Boolean
operators, truncations, proximity operators, and Medical
Subject Heading (MeSH), as appropriate. An illustrative
search used in PubMed is shown in supplemental file 2.
To identify additional relevant citations, reference lists of
included papers as well as “cited by” and “related citation”
tools in Google Scholar and PubMed, respectively, were
used. Three authors of ongoing studies and abstracts
were contacted for information regarding additional data
and peer-reviewed publications. No other limits were
applied.
Inclusion and exclusion criteria
Study design
All study designs, including quantitative and qualitative studies,
were considered eligible. Qualitative evidence regarding parti-
cipants’ perspectives was included to provide a context for
quantitative findings [19]. Non-original research, secondary
reports, commentaries, editorials, and reviews were excluded.
Domain
Studies were included if they were related to oral PrEP for
HIV prevention. Studies that did not report findings related
to PrEP were excluded.
Population
Studies were included if they reported data generated from
HIV-negative MSM in LMIC, regardless of age. Studies that
reported data from MSM together with other populations
such as TG or sex workers were included, but only data
related to MSM were considered and abstracted.
Intervention
The review included studies that reported awareness or
willingness to use PrEP. Studies that involved actual provi-
sion of PrEP and reported acceptability, such as clinical
trials and open-label extensions of trials, were not the
focus of this study and were excluded (Figure 1).
Awareness and knowledge of 
pre-exposure prophylaxis
Focus of this review
Theoretical willingness to use if it 
were made available
Actual provision and utilisation of 
pre-exposure prophylaxis in trials 
or open label extensions
Figure 1. Scope of this review.
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Comparator
As this was a descriptive review, studies were included
regardless of whether they reported outcomes from a con-
trol or counterfactual arm.
Outcomes
Relevant patient-related primary outcomes included aware-
ness of and willingness to use oral PrEP as shown in Table 1
below. The review elaborated on factors affecting the
potential willingness to use PrEP where these were pro-
vided in the included studies, and mapped these factors
across individual, social, and structural contexts of the
socio-ecological model. The socio-ecological model is
based on the assumption that individual health is deter-
mined by factors that are located within an individual, as
well as those in their environment [20]. The model has
been employed by other scholars to map the location of
factors that affect health service utilization [21,22].
Study selection, and data abstraction and
management
Using End-Note software version 7 (http://endnote.com/), all
citations were imported and duplicates removed. Three review
team members independently screened references in two
stages. In the first stage, titles and abstracts were screened to
exclude ineligible studies based on relevance. In the second
stage, full-text versions of selected papers were assessed inde-
pendently by three reviewers to ensure that inclusion criteria
were met. At each stage, selected papers were compared
between the three reviewers for concordance. Screening and
selection of studies were facilitated by the creation of appro-
priately labelled sub-folders in EndNote. In the event of uncer-
tainty or disagreement, the three reviewers conferred and
discussed with each other to reach a consensus. Data were
abstracted into a standardized form with the following fields:
authors, year of publication, country of study, design, settings,
study populations, outcomes and limitations. To aid conceptual
understanding of qualitative findings, typical participant quotes
relating to awareness or willingness to use PrEP were also
abstracted. A translator was utilized to translate three
Chinese abstracts and the corresponding full papers which
were subsequently included in the review.
Data analyses
All available data were pooled and synthesized using a combi-
nation of ameta-analysis and narrative synthesis approach. The
latter uses descriptive words and texts to summarize and
explain results from a review [23]. For quantitative studies,
proportions of participants who were aware or willing to use
PrEP were abstracted and reported. A synthesis of factors
determining willingness to use PrEP was performed, and
these were classified as being individual, social, or structural
in nature. Qualitative data were drawn on to provide context
for the quantitative findings as recommended [19,24], by iden-
tifying participant perspectives about factors that may affect
awareness and willingness to use PrEP among MSM. Using
thematic analysis [25–27], relevant quotes were abstracted,
sorted, compared, and categorized to construct a set of emer-
ging descriptive themes. Themes were then used to populate a
conceptual framework [28] of willingness to use PrEP at the
individual, social, and structural domains. In keeping with the
review protocol, meta-analyses were performed on the pri-
mary quantitative outcomes using a random effects model for
pooling proportions [29], but pooled results from fixed effects
models were displayed in graphical outputs to aid comparison
and discussion. Subgroup analyses were not performed.
Bias assessment
Three reviewers evaluated the risk of different types of
biases, including selection bias, attrition bias, and informa-
tion and reporting bias using methodology suggested in the
Cochrane Collaboration’s tool for assessing risk of bias [30].
Studies were included regardless of risk of bias, but the
impact of their inclusion on the robustness of findings and
conclusions was discussed.
Results
Study selection
This review involved a total of 2186 records. The initial
screening excluded duplicates (n = 733) and studies that
did not specifically focus on PrEP (n = 1238), leaving a
total of 213 citations. Subsequently, 192 citations were
excluded after screening the abstracts and full papers. A
few papers focusing on other populations (e.g. hetero-
sexual couples, sex workers, and TG populations) had
been identified through the search and were excluded
(n = 9). Additional exclusions were due to a variety of
reasons, including poor relevance of outcomes (e.g. cost
effectiveness; n = 118), failure to segregate results by
population (n = 13), and for being reviews (n = 7) or non-
peer reviewed articles (n = 45). In total, 2161 records
from the initial search were rejected for failing to meet
the inclusion criteria. An additional two Chinese citations
were identified from reference lists of included papers.
Table 1. Primary and secondary outcomes of this review
Outcome level Definition
Awareness of PrEP Proportion of MSM participants who reported knowing about PrEP
Willingness to use PrEP Proportion of MSM participants who reported being willing to use PrEP if it was available
Factors affecting willingness to use PrEP Individual, social, or structural factors that may determine the potential future use of PrEP
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Three authors were contacted to provide full papers or
additional data to that reported in their abstracts, but
these papers were not additional as they had been iden-
tified in the original search. In accordance with PRISMA
guidelines for a systematic review [17], a flow diagram
illustrating the literature search, article selection, and
final included studies is shown below (Figure 2).
Methods and study designs of included studies
We included 23 studies published between 2011 and
2016, and involving 15,014 MSM, of whom 14,040 were
from LMIC. Of these, three were published in Chinese, and
the rest were in English. Of the included studies, 19 were
quantitative, two were qualitative, and two were mixed
methods. These 23 studies related to 22 distinct popula-
tions. Two Malaysian studies conducted by Lim et al. [31]
and Bourne et al. [32] were linked in that participants of
the quantitative study were invited to participate in fol-
low-on qualitative interviews. All of the quantitative stu-
dies were cross-sectional surveys. The study by Wheelock
et al. [33] was a replication of that by Eisingerich et al.
[34], but in a different country. The following tables pre-
sent the key characteristics of the quantitative (Table 2)
mixed-methods (Table 3) and qualitative studies (Table 4)
included in the review.
Recruitment and data collection settings
Most studies were conducted in urban areas. Five studies
used internet-based advertisement and recruitment, includ-
ing Facebook or organizational websites [31,35,38], often in
combination with mobile-based social dating applications
(such as Grindr) [31] as well as TV and newspaper adver-
tisements [38]. Several studies used face-to-face recruit-
ment, exclusively or in combination with online methods.
Five studies sampled participants from service provision
sites such as community-based and youth-led non-govern-
mental organizations [31,32,50,52]. Two studies utilized
health facilities for recruitment and data collection, includ-
ing community health clinics [53] and HIV voluntary coun-
selling and testing sites [51]. Three studies utilized other
venues frequented by MSM such as entertainment venues
[33,47], gay community events [53], and beauty salons [50].
Other sites of recruitment included parks, volley-ball courts,
and streets [50].
Geographical location of included studies
Two studies conducted by Ayala et al. [35] and Eisingerich
et al. [34] were multi-country in scope, while all the rest
were conducted in a single country. The 21 single-country
studies had MSM participants from Brazil, China, India,
Kenya, Malaysia, Myanmar, Peru, Thailand, Uganda,
Vietnam, and South Africa. China contributed to most stu-
dies (n = 8), followed by Peru (n = 3), and Thailand (n = 3).
The study by Ayala et al. [35] was conducted in 145 coun-
tries, which included high-income countries as highlighted
in Table 2. At the time of the review, almost all of the
countries from which the participants in this review were
based were classified by the World Bank as either middle-
or upper-middle income, except Uganda which was a low-
income country (http://data.worldbank.org/country).
Description of participants in the included
studies
Together, the included studies involved a total of 15,014
MSM. Of these 14,040 were from LMIC. (some few TG
participants may be included where they were not sepa-
rated from MSM in two papers). The profile of MSM
included in the studies within the review included homo-
sexual and bisexual MSM. In total, eight studies from Brazil
[39], China [46,47,49], and Kenya [51] included participants
who described themselves as bisexual. The proportion of
participants that were bisexual was highest in the Kenyan
study by Karuga et al. [51] at 50.1%. Several studies
included MSM who were sex workers. In Karuga et al.
[51], 11.8% of participants were sex workers, while,
Oldenburg et al. [41] purposely recruited an exclusive sam-
ple of MSM sex workers.
Apart from MSM, several studies included other popula-
tions, although only data related to MSM were abstracted.
For example, Galea et al. [50] focused on MSM, female sex
workers, and TG populations in Peru. In their study,
Eisingerich et al. [34] included intravenous drug users,
Excluded (n=192):
Focussed on populations other 
than MSM (n=9)
Focussed on other outcomes 
(n=118)
Did not segregate MSM results 
(n=13)
Reviews and non-peer reviewed 
articles (n=52)
Total database search (n=2184):
CINAHL (n=42)
Embase (n=385)
Pubmed (n=254)
PsychINFO (n=95)
Google Scholar (n=997)
Web of Science (n=344)
Cochrane Library (n=67)
Excluded (n=1,971):
Not focussed on PrEP (n=1238)
Duplicates (n=733)
Records after initial screening (n=213)
Additional citations from reference list 
search (n=2, Chinese)
Included articles (n=23)
Figure 2. Study selection.
Yi S et al. Journal of the International AIDS Society 2017, 20:21580
http://www.jiasociety.org/index.php/jias/article/view/21580 | http://dx.doi.org/10.7448/IAS.20.1.21580
4
Ta
b
le
2.
C
h
ar
ac
te
ri
st
ic
s
an
d
fi
n
d
in
gs
o
f
q
u
an
ti
ta
ti
ve
st
u
d
ie
s
in
cl
u
d
ed
in
th
e
sy
st
em
at
ic
re
vi
ew
A
u
th
o
r,
ye
ar
C
o
u
n
tr
y
an
d
se
tt
in
g
D
es
ig
n
Sa
m
p
le
si
ze
P
ar
ti
ci
p
an
ts
’
ch
ar
ac
te
ri
st
ic
s
A
w
ar
en
es
s
W
ill
in
gn
es
s
to
u
se
Fa
ct
o
rs
as
so
ci
at
ed
w
it
h
w
ill
in
gn
es
s
to
u
se
A
ya
la
et
al
.,
20
13
14
5
co
u
n
tr
ie
s-
A
fr
ic
a,
A
si
a,
Eu
ro
p
e
an
d
La
ti
n
A
m
er
ic
a.
O
n
lin
e
su
rv
ey
.
27
74
M
SM
.α
A
ge
ra
n
ge
w
as
12
–9
0
ye
ar
s.
69
.8
%
o
f
th
e
re
sp
o
n
d
en
ts
w
er
e
aw
ar
e.
α
80
.8
%
w
er
e
w
ill
in
g
to
us
e
Pr
EP
.α
Pr
EP
st
ig
m
a
(β
:
−
0.
51
;
95
%
C
I=
−
0.
55
to
−
0.
48
,
p<
0.
00
1)
,
o
u
tn
es
s
(β
:
−
0.
15
;
95
%
C
I=
−
0.
18
to
−
0.
12
,
p<
0.
00
1)
,
an
d
kn
o
w
le
d
ge
ab
o
u
t
Pr
EP
(β
:
−
0.
14
;
95
%
C
I=
−
0.
18
to
−
0.
10
,
p<
0.
00
1)
w
er
e
n
eg
at
iv
el
y
co
rr
el
at
ed
w
it
h
ac
ce
p
ta
b
ili
ty
o
f
Pr
EP
.
A
cc
ep
ta
b
ili
ty
o
f
Pr
EP
w
as
p
o
si
ti
ve
ly
co
rr
el
at
ed
w
it
h
h
av
in
g
ex
p
er
ie
n
ce
d
se
rv
ic
e
p
ro
vi
d
er
st
ig
m
a
(β
:
0.
12
;
95
%
C
I=
0.
02
–0
.2
3,
p=
0.
02
1)
.
R
es
p
o
n
d
en
ts
in
h
ig
h
-i
n
co
m
e
co
u
n
tr
ie
s
re
p
o
rt
ed
lo
w
er
ac
ce
p
ta
b
ili
ty
o
f
Pr
EP
th
an
th
o
se
fr
o
m
LM
IC
.
D
in
g
et
al
.,2
01
6
Sh
an
gh
ai
,
C
h
in
a.
Su
rv
ey
.
1,
03
3
M
SM
.
76
%
se
lf
-
id
en
ti
fi
ed
as
ga
y
an
d
2.
5%
w
er
e
al
re
ad
y
u
si
n
g
Pr
EP
.
N
o
t
re
p
o
rt
ed
.
19
.1
%
w
ill
in
g
to
u
se
Pr
EP
.
W
ill
in
gn
es
s
to
u
se
Pr
EP
w
as
as
so
ci
at
ed
w
it
h
o
ld
er
ag
e
(≥
45
ye
ar
s
(A
d
ju
st
ed
O
d
d
s
R
at
io
(A
O
R
):
2.
18
;
95
%
(C
o
n
fi
d
en
ce
In
te
rv
al
(C
I)
=1
.1
3–
4.
23
,
p=
0.
00
6)
,
im
m
ig
ra
ti
o
n
to
Sh
an
gh
ai
(2
1.
5%
am
o
n
g
im
m
ig
ra
n
ts
vs
15
.9
%
am
o
n
g
lo
ca
l
re
si
d
en
ts
;
A
O
R
:
1.
69
;
95
%
C
I=
1.
16
–2
.4
5,
p=
0.
02
6)
,
tw
o
o
r
m
o
re
m
al
e
se
x
p
ar
tn
er
s
in
th
e
p
as
t
6
m
o
n
th
s
(A
O
R
:1
.5
3;
95
%
C
I=
1.
07
–
2.
17
,
p=
0.
02
).
C
o
n
d
o
m
u
se
at
la
st
an
al
se
x
w
it
h
m
an
w
er
e
si
gn
if
ic
an
tl
y
le
ss
w
ill
in
g
to
u
se
Pr
EP
(A
O
R
:0
.6
8;
95
%
C
I=
0.
47
–0
.9
7,
p=
0.
03
4)
.
Ed
u
ca
ti
o
n
,
o
cc
u
p
at
io
n
,
ga
y
se
xu
al
id
en
ti
ty
,
an
d
m
ar
it
al
st
at
u
s
w
er
e
n
o
t
as
so
ci
at
ed
w
it
h
w
ill
in
gn
es
s
to
u
se
it
.
D
ra
p
er
et
al
.,
20
16
Ya
n
go
n
an
d
M
an
d
al
ay
in
M
ya
n
m
ar
.
Su
rv
ey
.
43
4
G
M
Tβ
N
o
t
re
p
o
rt
ed
.
5%
aw
ar
e.
62
%
w
er
e
w
ill
in
g
to
u
se
Pr
EP
am
o
n
g
43
4
H
IV
u
n
d
ia
gn
o
se
d
G
M
T.
W
ill
in
gn
es
s
to
u
se
Pr
EP
w
as
as
so
ci
at
ed
w
it
h
re
p
o
rt
in
g
n
ev
er
/
o
cc
as
io
n
al
u
se
o
f
co
n
d
o
m
s
co
m
p
ar
ed
to
al
w
ay
s/
m
o
st
ly
u
se
d
,
w
it
h
ca
su
al
p
ar
tn
er
s
(a
d
ju
st
ed
o
d
d
s
ra
ti
o
(A
O
R
:
2.
02
;
95
%
C
I=
1.
00
–4
.1
0)
,
re
si
d
en
ce
M
an
d
al
ay
(A
O
R
:1
.7
9;
95
%
C
I=
1.
05
-3
.0
3)
,
p
er
ce
iv
in
g
as
lik
el
y
to
b
ec
o
m
e
H
IV
p
o
si
ti
ve
(A
O
R
:1
.8
2;
95
%
C
I=
1.
10
–3
.0
2)
,
h
av
in
g
h
ad
m
o
re
th
an
o
n
e
re
gu
la
r
p
ar
tn
er
(A
O
R
=2
.9
4;
95
%
C
I=
1.
41
–6
.1
4)
o
r
n
o
re
gu
la
r
p
ar
tn
er
s
(A
O
R
:2
.0
5;
95
%
C
I=
1.
10
–3
.6
7)
o
r
m
o
re
th
an
fi
ve
ca
su
al
p
ar
tn
er
s
(A
O
R
:2
.0
5;
95
%
C
I=
1.
06
–3
.9
9)
o
r
n
o
ca
su
al
p
ar
tn
er
s
(A
O
R
:2
.2
5;
95
%
C
I=
1.
23
–4
.1
1)
in
th
e
p
as
t
th
re
e
m
o
n
th
s.
Th
o
se
re
p
o
rt
in
g
co
n
ce
rn
s
ab
o
u
t
Pr
EP
si
d
e-
ef
fe
ct
s
d
u
e
to
lo
n
g-
te
rm
u
se
w
er
e
le
ss
lik
el
y
to
b
e
w
ill
in
g
to
u
se
it
(A
O
R
:0
.3
5;
95
%
C
I=
0.
21
–0
.5
9)
.
Yi S et al. Journal of the International AIDS Society 2017, 20:21580
http://www.jiasociety.org/index.php/jias/article/view/21580 | http://dx.doi.org/10.7448/IAS.20.1.21580
5
Ta
b
le
2.
(C
on
ti
nu
ed
)
A
u
th
o
r,
ye
ar
C
o
u
n
tr
y
an
d
se
tt
in
g
D
es
ig
n
Sa
m
p
le
si
ze
P
ar
ti
ci
p
an
ts
’
ch
ar
ac
te
ri
st
ic
s
A
w
ar
en
es
s
W
ill
in
gn
es
s
to
u
se
Fa
ct
o
rs
as
so
ci
at
ed
w
it
h
w
ill
in
gn
es
s
to
u
se
Ei
si
n
ge
ri
ch
et
al
.,
20
12
Pe
ru
,
In
d
ia
,
So
u
th
A
fr
ic
a.
Su
rv
ey
38
3
M
SM
γ
M
ea
n
ag
e
o
f
M
SM
n
o
t
re
p
o
rt
ed
;
39
%
w
er
e
ag
ed
16
-2
4,
an
d
6%
w
er
e
ag
ed
≥
41
ye
ar
s.
N
o
t
re
p
o
rt
ed
69
%
re
p
o
rt
ed
‘y
es
,
d
ef
in
it
el
y’
an
d
25
%
‘y
es
,
p
ro
b
ab
ly
’
ac
ro
ss
In
d
ia
,
Pe
ru
an
d
So
u
th
A
fr
ic
aβ
.
42
–6
9%
re
po
rt
ed
th
at
Pr
EP
w
ou
ld
gi
ve
th
em
“a
lo
t
of
ho
p
e”
.3
–
8%
re
po
rt
ed
th
at
Pr
EP
w
ou
ld
be
“v
er
y
em
b
ar
ra
ss
in
g”
to
ta
ke
.
In
di
an
an
d
Pe
ru
vi
an
M
SM
p
re
fe
rr
ed
bi
m
on
th
ly
in
je
ct
io
n
in
th
e
b
ut
to
ck
s
w
h
ile
So
u
th
A
fr
ic
an
M
SM
pr
ef
er
re
d
da
ily
p
ill
to
ar
m
in
je
ct
io
n
.O
f
th
os
e
w
ill
in
g
to
us
e
Pr
EP
,3
2–
72
%
w
er
e
w
ill
in
g
to
u
se
Pr
EP
de
sp
it
e
si
d
e
ef
fe
ct
s;
39
–8
8%
w
er
e
w
ill
in
g
to
u
se
it
d
es
p
it
e
h
av
in
g
to
pa
y,
32
–8
5%
w
er
e
w
ill
in
g
to
u
se
it
ev
en
if
h
av
in
g
to
us
e
co
nd
om
s,
an
d
55
–8
8%
w
er
e
w
ill
in
g
to
u
se
it
w
it
h
re
gu
la
r
H
IV
te
st
in
g.
H
e
et
al
.,
20
14
C
h
in
a.
Su
rv
ey
.
13
23
M
SM
δ
M
ea
n
ag
e=
28
ye
ar
s.
O
ve
ra
ll,
31
.4
%
h
ad
h
ea
rd
o
f
Pr
EP
.
N
o
t
re
p
o
rt
ed
.
Fa
ct
o
rs
af
fe
ct
in
g
u
se
w
er
e
n
o
t
re
p
o
rt
ed
;
h
o
w
ev
er
,
th
e
st
u
d
y
re
p
o
rt
ed
th
at
in
fo
rm
at
io
n
re
ga
rd
in
g
Pr
EP
sh
o
u
ld
b
e
p
ro
m
o
te
d
th
ro
u
gh
m
ed
ia
to
m
ak
e
su
re
M
SM
in
C
h
in
a
ca
n
ge
t
th
e
in
fo
rm
at
io
n
q
u
ic
kl
y
an
d
ea
si
ly
.
H
o
ag
la
n
d
et
al
.,
20
16
B
ra
zi
l.
C
ro
ss
-s
ec
ti
o
n
al
st
u
d
y.
11
31
M
SM
ε
M
ed
ia
n
ag
e=
29
ye
ar
s
46
.8
%
w
er
e
H
IV
p
o
si
ti
ve
.
61
.3
%
w
er
e
aw
ar
e.
82
.1
%
w
er
e
w
ill
in
g
to
u
se
Pr
EP
.
W
ill
in
gn
es
s
to
u
se
Pr
EP
w
as
hi
gh
er
am
on
g
th
os
e
aw
ar
e
of
Pr
EP
co
m
p
ar
ed
to
th
os
e
un
aw
ar
e
of
it
(8
5.
4%
vs
76
.9
%
;p
<0
.0
01
),
am
on
g
th
os
e
w
it
h
m
or
e
ye
ar
s
of
sc
ho
ol
in
g
(7
8.
1%
am
on
g
th
os
e
w
it
h
<1
2
ye
ar
s
vs
84
.5
%
am
on
g
th
os
e
w
it
h
≥
12
ye
ar
s
of
sc
h
oo
lin
g;
p=
0.
00
6)
,a
n
d
th
os
e
w
it
h
a
re
ce
nt
ST
D
d
ia
gn
os
is
in
la
st
12
m
on
th
s
co
m
pa
re
d
to
th
os
e
w
it
h
ou
t
(6
8.
8%
vs
60
.2
%
;
p
=0
.0
2)
.W
ill
in
gn
es
s
to
us
e
Pr
EP
w
as
no
t
as
so
ci
at
ed
w
it
h
ag
e.
C
om
p
ar
ed
w
it
h
th
os
e
ag
ed
18
–2
4
ye
ar
s,
w
ill
in
gn
es
s
to
us
e
Pr
EP
in
cr
ea
se
d
m
ar
gi
n
al
ly
am
on
g
25
–3
5y
ea
r
ol
d
s
(8
1.
02
%
,v
s
81
.7
%
;
p=
0.
85
)
an
d
am
on
g
th
os
e
ag
ed
≥
36
ye
ar
s
(8
1.
02
%
vs
84
.1
%
;
p=
0.
35
).
W
ill
in
gn
es
s
to
u
se
w
as
no
t
as
so
ci
at
ed
w
it
h
m
al
e
ge
n
de
r
co
m
p
ar
ed
to
tr
an
sg
en
d
er
(8
1.
8%
vs
89
.3
%
;
p=
0.
16
),
a
n
eg
at
iv
e
co
m
p
ar
ed
to
a
p
os
it
iv
e
H
IV
te
st
re
su
lt
(6
2.
7%
vs
46
.8
%
;
p=
0.
99
),
or
fa
ilu
re
to
pe
rf
or
m
a
te
st
(6
2.
7%
vs
65
.4
%
;p
=0
.4
0)
.7
5.
8
%
re
po
rt
ed
th
ey
w
ou
ld
u
se
Pr
EP
ev
en
if
th
ey
h
ad
to
p
ay
fo
r
it
.
Yi S et al. Journal of the International AIDS Society 2017, 20:21580
http://www.jiasociety.org/index.php/jias/article/view/21580 | http://dx.doi.org/10.7448/IAS.20.1.21580
6
Ta
b
le
2.
(C
on
ti
nu
ed
)
A
u
th
o
r,
ye
ar
C
o
u
n
tr
y
an
d
se
tt
in
g
D
es
ig
n
Sa
m
p
le
si
ze
P
ar
ti
ci
p
an
ts
’
ch
ar
ac
te
ri
st
ic
s
A
w
ar
en
es
s
W
ill
in
gn
es
s
to
u
se
Fa
ct
o
rs
as
so
ci
at
ed
w
it
h
w
ill
in
gn
es
s
to
u
se
Ja
ck
so
n
et
al
.,
20
12
G
u
an
gx
i,
Si
ch
u
an
an
d
C
h
o
n
gq
in
g,
C
h
in
a.
Su
rv
ey
.
57
0
M
SM
M
ea
n
ag
e=
27
.6
ye
ar
s;
ag
e
ra
n
ge
=1
8–
62
ye
ar
s,
an
d
76
.8
%
w
er
e
u
rb
an
d
w
el
le
rs
.
N
o
t
re
p
o
rt
ed
.
63
%
h
ad
h
ig
h
w
ill
in
gn
es
s
to
u
se
Pr
EP
,
w
h
ile
22
.8
%
h
ad
lo
w
er
w
ill
in
gn
es
s
to
u
se
it
.
W
ill
in
gn
es
s
to
u
se
Pr
EP
w
as
as
so
ci
at
ed
w
it
h
u
rb
an
co
m
p
ar
ed
th
an
ru
ra
l
re
si
d
en
ce
,
h
ig
h
er
ed
u
ca
ti
o
n
at
ta
in
m
en
t
(2
.2
%
am
o
n
g
p
ri
m
ar
y
sc
h
o
o
l,
vs
10
.3
%
am
o
n
g
m
id
d
le
sc
h
o
o
l,
vs
38
.2
%
h
ig
h
sc
h
o
o
l
vs
49
.3
%
am
o
n
g
th
o
se
w
it
h
u
n
d
er
gr
ad
u
at
e
o
r
h
ig
h
er
ed
u
ca
ti
o
n
;
p
<0
.0
01
),
lo
w
er
m
o
n
th
ly
p
er
so
n
al
in
co
m
e
(3
7.
9%
am
o
n
g
th
o
se
ea
rn
in
g
1,
00
0
Yu
an
o
r
le
ss
vs
2.
8%
am
o
n
g
th
o
se
ea
rn
in
g
5,
00
0
Yu
an
o
r
m
o
re
.
O
cc
u
p
at
io
n
al
st
at
u
s
an
d
p
re
vi
o
u
s
ex
p
er
ie
n
ce
o
f
ST
Iw
er
e
n
o
t
as
so
ci
at
ed
w
it
h
w
ill
in
gn
es
s
to
u
se
Pr
EP
.S
ti
gm
a
o
f
Pr
EP
w
as
a
p
o
te
n
ti
al
b
ar
ri
er
,
w
h
ile
p
er
ce
iv
ed
b
en
ef
it
s
o
f
Pr
EP
w
as
a
fa
ci
lit
at
o
rs
o
f
p
o
te
n
ti
al
u
se
.
Ko
et
al
.,
20
16
Ta
iw
an
.
O
n
lin
e
su
rv
ey
.
11
51
M
SM
M
ea
n
ag
e=
25
.9
ye
ar
s,
ag
e
ra
n
ge
=1
8–
53
ye
ar
s,
m
o
st
w
er
e
fr
o
m
th
e
n
o
rt
h
(4
8.
5%
),
h
ad
p
ro
fe
ss
io
n
al
q
u
al
if
ic
at
io
n
(6
1.
2%
)
an
d
w
er
e
em
p
lo
ye
d
(5
7.
0%
).
N
o
t
re
p
o
rt
ed
56
%
w
er
e
w
ill
in
g
to
u
se
Pr
EP
.
O
f
th
o
se
w
ill
in
g
to
u
se
Pr
EP
,
70
%
w
er
e
w
ill
in
g
to
ta
ke
p
ill
s
b
ef
o
re
an
d
af
te
r
se
x,
61
%
w
er
e
w
ill
in
g
to
ta
ke
Pr
EP
to
p
re
ve
n
t
ge
tt
in
g
H
IV
,
43
.7
%
w
er
e
w
ill
in
g
to
ta
ke
a
p
ill
d
ai
ly
,
44
.4
%
w
er
e
w
ill
in
g
to
ta
ke
Pr
EP
ev
en
if
it
w
as
n
o
t
10
0%
ef
fe
ct
iv
e,
an
d
o
n
ly
23
%
w
er
e
w
ill
in
g
to
se
lf
-p
ay
Ta
iw
an
$
34
0
fo
r
Pr
EP
.W
ill
in
gn
es
s
to
u
se
Pr
EP
in
cr
ea
se
d
w
it
h
te
rt
ia
ry
co
m
p
ar
ed
w
it
h
se
co
n
d
ar
y
ed
u
ca
ti
o
n
(3
0.
7%
vs
2.
2%
;
p
<0
.0
5)
,
an
d
am
o
n
g
th
o
se
w
it
h
p
ro
fe
ss
io
n
al
q
u
al
if
ic
at
io
n
(5
4.
8%
vs
12
.2
%
;
p
<0
.0
5)
,
an
d
a
p
as
t
h
is
to
ry
o
f
re
ce
iv
in
g
H
IV
n
o
n
-o
cc
u
p
at
io
n
al
PE
P
(5
.9
%
vs
3.
2%
;
p
va
lu
e
<0
.0
1)
.
Th
er
e
w
as
n
o
d
if
fe
re
n
ce
in
ag
e
o
r
em
p
lo
ym
en
t
b
et
w
ee
n
p
ar
ti
ci
p
an
ts
w
h
o
w
er
e
w
ill
in
g
to
u
se
Pr
EP
an
d
th
o
se
w
h
o
w
er
e
n
o
t.
Yi S et al. Journal of the International AIDS Society 2017, 20:21580
http://www.jiasociety.org/index.php/jias/article/view/21580 | http://dx.doi.org/10.7448/IAS.20.1.21580
7
Ta
b
le
2.
(C
on
ti
nu
ed
)
A
u
th
o
r,
ye
ar
C
o
u
n
tr
y
an
d
se
tt
in
g
D
es
ig
n
Sa
m
p
le
si
ze
P
ar
ti
ci
p
an
ts
’
ch
ar
ac
te
ri
st
ic
s
A
w
ar
en
es
s
W
ill
in
gn
es
s
to
u
se
Fa
ct
o
rs
as
so
ci
at
ed
w
it
h
w
ill
in
gn
es
s
to
u
se
Li
m
et
al
.,
20
16
Ku
al
ar
Lu
m
p
u
r,
M
al
ay
si
a.
Su
rv
ey
(o
n
lin
e)
.
99
0
M
SM
ϕ
80
.4
%
se
lf
-i
d
en
ti
fi
ed
as
h
o
m
o
se
xu
al
an
d
16
.6
%
as
b
is
ex
u
al
.
A
ge
ra
n
ge
=1
6–
68
.
O
ve
ra
ll
19
.6
%
w
er
e
ag
ed
<2
5
ye
ar
s.
In
ad
d
it
io
n
,
87
.2
%
h
ad
p
o
st
-s
ec
o
n
d
ar
y
ed
u
ca
ti
o
n
an
d
85
.2
%
w
er
e
in
p
ar
t-
ti
m
e
o
r
fu
ll
ti
m
e
em
p
lo
ym
en
t.
44
%
w
er
e
aw
ar
e
o
f
Pr
EP
.
39
%
w
er
e
w
ill
in
g
to
u
se
Pr
EP
.
R
ec
en
t
ST
I
d
ia
gn
o
si
s
in
th
e
p
as
t
12
m
o
n
th
s
w
as
as
so
ci
at
ed
w
it
h
h
ig
h
lik
el
ih
o
o
d
to
u
se
co
m
p
ar
ed
to
th
o
se
w
it
h
n
o
su
ch
d
ia
gn
o
si
s
(4
3.
3%
vs
36
.1
%
;
p=
0.
00
3)
.
M
al
ay
p
ar
ti
ci
p
an
ts
m
o
re
lik
el
y
to
u
se
Pr
EP
(4
8.
6%
)
co
m
p
ar
ed
to
C
h
in
es
e
(3
2.
7%
),
In
d
ia
n
(3
2.
8%
)
an
d
m
ix
ed
an
d
o
th
er
ra
ce
s
(3
6.
7%
;
p
<0
.0
01
).
W
ill
in
gn
es
s
to
u
se
Pr
EP
w
as
n
o
t
as
so
ci
at
ed
w
it
h
ag
e,
re
si
d
en
ce
in
Ku
al
a
Lu
m
p
u
r,
ed
u
ca
ti
o
n
,
em
p
lo
ym
en
t
st
at
u
s,
o
r
in
co
m
e.
A
th
ir
d
(3
5.
6%
)
w
er
e
w
ill
in
g
to
p
ay
fo
r
Pr
EP
.
H
o
w
ev
er
,
o
f
th
es
e
th
e
m
aj
o
ri
ty
(8
8.
3%
)
w
er
e
n
o
t
w
ill
in
g
to
sp
en
d
o
ve
r
20
0
R
M
(U
SD
50
)
o
n
Pr
EP
p
er
m
o
n
th
.
O
f
th
e
60
3
p
ar
ti
ci
p
an
ts
w
h
o
re
p
o
rt
ed
n
o
t
w
ill
in
g
to
u
se
Pr
EP
,
th
e
re
as
o
n
s
o
ff
er
ed
w
er
e
si
d
e
ef
fe
ct
s
(1
8.
6%
),
fe
ar
th
at
Pr
EP
w
o
n
’t
w
o
rk
(9
.8
%
),
w
o
rr
y
ab
o
u
t
fo
rg
et
ti
n
g
to
ta
ke
m
ed
ic
at
io
n
(8
.3
%
),
o
r
w
h
at
o
th
er
p
eo
p
le
m
ig
h
t
th
in
k
o
f
th
em
(5
.8
%
),
fa
ilu
re
to
af
fo
rd
Pr
EP
(8
.8
%
),
o
r
th
e
fa
ct
th
at
th
ey
al
w
ay
s
u
se
a
co
n
d
o
m
an
d
th
er
ef
o
re
w
o
u
ld
n
o
t
n
ee
d
Pr
EP
(1
1.
4%
).
O
ld
en
b
u
rg
et
al
.,
20
16
H
o
C
h
i
M
in
h
ci
ty
,
V
ie
tn
am
.
Su
rv
ey
.
30
0
M
SM
γ
93
.7
%
w
er
e
H
IV
n
eg
at
iv
e,
an
d
27
%
w
er
e
ag
ed
15
–1
9
ye
ar
s.
N
o
t
re
p
o
rt
ed
.
95
.4
%
w
er
e
w
ill
in
g
to
u
se
Pr
EP
d
ai
ly
.η
O
ve
ra
ll,
56
.7
%
w
ill
in
g
to
ta
ke
Pr
EP
gi
ve
n
si
d
e
ef
fe
ct
s,
an
d
27
.7
%
p
re
fe
rr
ed
a
Pr
EP
lu
b
ri
ca
n
t
to
a
p
ill
.
Pr
ev
io
u
s
co
n
ta
ct
w
it
h
Pe
er
H
ea
lt
h
Ed
u
ca
to
rs
w
as
as
so
ci
at
ed
w
it
h
h
ig
h
er
w
ill
in
gn
es
s
to
u
se
(A
O
R
:
2.
28
;
95
%
C
I=
1.
25
–4
.1
4,
p<
0.
05
).
Pe
in
ad
o
et
al
.,
20
13
Li
m
a,
Iq
u
it
o
s
an
d
Pu
ca
llp
a,
Pe
ru
.
Su
rv
ey
(s
ec
o
n
d
ar
y
an
al
ys
is
).
53
2
M
SM
an
d
TG
ι
M
ed
ia
n
ag
e=
28
ye
ar
s;
ra
n
ge
16
–6
8
ye
ar
s.
N
o
t
re
p
o
rt
ed
.
96
.2
%
w
er
e
w
ill
in
g
to
u
se
o
ra
l
Pr
EP
w
h
ile
91
.7
%
w
er
e
w
ill
in
g
to
u
se
re
ct
al
Pr
EP
A
ft
er
ad
ju
st
m
en
t
fo
r
ag
e,
ci
ty
,
an
d
ed
u
ca
ti
o
n
,
o
n
ly
b
ei
n
g
re
ce
p
ti
ve
m
o
st
o
f
th
e
ti
m
e
(A
O
R
:
9.
1;
95
%
C
I=
1.
8–
46
.5
,
p=
0.
01
)
an
d
ex
cl
u
si
ve
ly
re
ce
p
ti
ve
(A
O
R
:7
.5
;
95
%
C
I=
1.
6-
53
.2
,
p=
0.
01
)
d
u
ri
n
g
an
al
in
te
rc
o
u
rs
e,
co
m
p
ar
ed
to
b
ei
n
g
ve
rs
at
ile
,
w
er
e
in
d
ep
en
d
en
tl
y
as
so
ci
at
ed
w
it
h
ac
ce
p
ta
b
ili
ty
to
u
se
o
ra
l
Pr
EP
.
Si
n
ea
th
et
al
.,
20
13
Th
ai
la
n
d
.
Su
rv
ey
(o
n
lin
e)
40
4
M
SM
.φ
M
ea
n
ag
e
w
as
=2
5
ye
ar
s.
7%
w
er
e
aw
ar
e
o
f
Pr
EP
.
36
%
w
er
e
w
ill
in
g
to
u
se
af
te
r
Pr
EP
w
as
d
es
cr
ib
ed
.
O
f
th
o
se
w
ill
in
g
to
u
se
Pr
EP
65
%
in
d
ic
at
ed
th
ey
w
o
u
ld
b
e
w
ill
in
g
to
p
ay
fo
r
it
.
O
ve
ra
ll,
34
%
“d
id
n
’t
w
an
t
to
h
av
e
to
ta
ke
m
ed
ic
at
io
n
ev
er
y
d
ay
”
an
d
28
%
“d
id
n
’t
w
an
t
to
go
se
e
th
e
d
o
ct
o
r
ev
er
y
th
re
e
m
o
n
th
s”
.
In
ad
d
it
io
n
,
35
%
b
el
ie
ve
d
co
n
d
o
m
s
w
er
e
m
o
re
ef
fe
ct
iv
e
th
an
Pr
EP
.
W
ei
et
al
.,
20
11
G
u
an
gx
i,
C
h
in
a.
Su
rv
ey
(f
ac
e
to
fa
ce
).
65
0
M
SM
.
M
ea
n
ag
e=
28
ye
ar
s
19
.7
%
h
ad
h
ea
rd
ab
o
u
t
Pr
EP
.
91
.9
%
w
er
e
w
ill
in
g
to
u
se
Pr
EP
if
fr
ee
an
d
sa
fe
.
Si
d
e
ef
fe
ct
s
an
d
ef
fi
ca
cy
o
f
Pr
EP
w
er
e
re
p
o
rt
ed
as
in
fl
u
en
ci
n
g
w
ill
in
gn
es
s
to
u
se
.
Yi S et al. Journal of the International AIDS Society 2017, 20:21580
http://www.jiasociety.org/index.php/jias/article/view/21580 | http://dx.doi.org/10.7448/IAS.20.1.21580
8
Ta
b
le
2.
(C
on
ti
nu
ed
)
A
u
th
o
r,
ye
ar
C
o
u
n
tr
y
an
d
se
tt
in
g
D
es
ig
n
Sa
m
p
le
si
ze
P
ar
ti
ci
p
an
ts
’
ch
ar
ac
te
ri
st
ic
s
A
w
ar
en
es
s
W
ill
in
gn
es
s
to
u
se
Fa
ct
o
rs
as
so
ci
at
ed
w
it
h
w
ill
in
gn
es
s
to
u
se
W
h
ee
lo
ck
et
al
.,
20
13
B
an
gk
o
k
an
d
C
h
ia
n
g
M
ai
,
Th
ai
la
n
d
.
Su
rv
ey
.
26
0
M
SM
.
4%
an
d
54
%
w
er
e
16
–1
8
an
d
19
–2
4
ye
ar
s,
re
sp
ec
ti
ve
ly
.
El
ig
ib
le
p
ar
ti
ci
p
an
ts
w
er
e
at
le
as
t
16
ye
ar
s.
94
%
h
ad
p
o
st
-s
ec
o
n
d
ar
y
ed
u
ca
ti
o
n
.
N
o
t
re
p
o
rt
ed
.
39
.2
%
re
p
o
rt
ed
th
ey
w
o
u
ld
‘d
ef
in
it
el
y’
an
d
49
.2
%
w
o
u
ld
‘p
ro
b
ab
ly
’
u
se
Pr
EP
.
O
f
th
o
se
w
ill
in
g
to
u
se
Pr
EP
,5
8.
8%
w
er
e
‘d
ef
in
it
el
y’
w
h
ile
35
%
w
er
e
‘p
ro
b
ab
ly
’
w
ill
in
g
to
u
se
Pr
EP
d
es
p
it
e
h
av
in
g
to
p
ay
50
0
B
ah
t
a
m
o
n
th
fo
r
it
.
2.
7%
re
p
o
rt
ed
th
at
ta
ki
n
g
Pr
EP
w
o
u
ld
b
e
‘v
er
y
em
b
ar
ra
ss
in
g’
an
d
5.
8%
re
p
o
rt
ed
th
at
it
w
o
u
ld
b
e
‘f
ai
rl
y
em
b
ar
ra
ss
in
g’
.
D
ai
ly
p
ill
w
as
th
e
p
re
fe
rr
ed
ro
u
te
o
f
ad
m
in
is
tr
at
io
n
fo
llo
w
ed
b
y
a
m
o
n
th
ly
in
je
ct
io
n
in
th
e
ar
m
.
A
ft
er
le
ar
n
in
g
o
f
p
o
te
n
ti
al
m
ild
si
d
e
ef
fe
ct
s,
24
.6
%
w
er
e
‘d
ef
in
it
el
y’
an
d
56
.5
%
‘p
ro
b
ab
ly
’
w
ill
in
g
to
u
se
Pr
EP
.
Xi
a
et
al
.,
20
16
W
u
h
an
an
d
Sh
an
gh
ai
,
C
h
in
a.
Su
rv
ey
.
48
7
M
SM
M
ea
n
ag
e=
28
;
ra
n
ge
18
–
62
;
ye
ar
s.
31
.7
%
w
er
e
ag
ed
18
–2
4
an
d
53
.5
%
w
er
e
ag
ed
25
–
34
ye
ar
s.
81
.1
%
se
lf
-
id
en
ti
fi
ed
as
ga
y,
an
d
16
.2
%
as
b
is
ex
u
al
.
73
%
w
er
e
ed
u
ca
te
d
to
co
lle
ge
le
ve
l,
61
.4
%
w
er
e
em
p
lo
ye
d
,
51
.1
%
ea
rn
ed
b
et
w
ee
n
20
01
–5
00
0
R
M
B
an
d
7%
h
ad
b
ee
n
d
ia
gn
o
se
d
w
it
h
an
ST
I
in
th
e
la
st
ye
ar
.
19
.1
%
aw
ar
e.
71
.3
%
w
ill
in
g
to
u
se
.
W
ill
in
gn
es
s
to
u
se
Pr
EP
w
as
as
so
ci
at
ed
w
it
h
m
ar
it
al
st
at
u
s:
84
.4
%
o
f
th
o
se
m
ar
ri
ed
/c
o
h
ab
it
in
g
w
er
e
w
ill
in
g
to
u
se
Pr
EP
ve
rs
u
s
67
.5
%
o
f
u
n
m
ar
ri
ed
/d
iv
o
rc
ed
o
r
w
id
o
w
ed
(p
=0
.0
01
).
B
is
ex
u
al
(7
7.
2%
)
w
er
e
m
o
re
lik
el
y
to
u
se
it
co
m
p
ar
ed
to
ga
y
p
ar
ti
ci
p
an
ts
(7
1.
1%
)
o
r
/o
th
er
/u
n
su
re
(3
8.
5%
;
p=
0.
01
7)
.
W
ill
in
gn
es
s
to
u
se
w
as
as
so
ci
at
ed
w
it
h
ta
ki
n
g
an
ST
I
te
st
in
th
e
la
st
12
m
o
n
th
s
co
m
p
ar
ed
to
th
o
se
th
at
d
id
n
’t
(7
6%
vs
.
63
.4
%
;
p=
0.
00
7)
b
u
t
w
as
in
ve
rs
el
y
as
so
ci
at
ed
w
it
h
b
ei
n
g
d
ia
gn
o
se
d
w
it
h
an
ST
I
in
la
st
12
m
o
n
th
s
co
m
p
ar
ed
to
th
o
se
n
o
t
d
ia
gn
o
se
d
,
th
o
u
gh
n
o
t
si
gn
if
ic
an
t
(6
7.
6%
vs
72
.6
%
;
p=
0.
06
5)
.M
en
u
si
n
g
th
e
in
te
rn
et
w
er
e
m
o
re
lik
el
y
to
re
p
o
rt
w
ill
in
gn
es
s
to
u
se
Pr
EP
co
m
p
ar
ed
to
th
o
se
w
h
o
h
ea
rd
ab
o
u
t
Pr
EP
fa
ce
-t
o
-f
ac
e
(7
5.
2%
vs
66
.4
%
;
p <
0.
05
).
W
ill
in
gn
es
s
to
u
se
w
as
n
o
t
as
so
ci
at
ed
w
it
h
ag
e
o
r
d
u
ra
ti
o
n
o
f
re
si
d
en
cy
in
th
e
ci
ty
.
Xu
e
et
al
.
20
15
C
h
in
a.
Su
rv
ey
(o
n
lin
e)
.
76
0
M
SM
κ
77
.2
%
se
lf
-i
d
en
ti
fi
ed
as
h
o
m
o
se
xu
al
an
d
20
%
re
m
ai
n
d
er
as
b
is
ex
u
al
72
.8
%
aw
ar
e
o
f,
o
r
fu
lly
u
n
d
er
st
o
o
d
Pr
EP
.
32
.1
%
w
o
u
ld
p
o
ss
ib
ly
u
se
Pr
EP
.
61
%
(3
05
/5
00
)
w
o
u
ld
p
o
ss
ib
ly
ta
ke
Pr
EP
o
ra
lly
d
ai
ly
.
Fa
ct
o
rs
th
at
w
er
e
id
en
ti
fi
ed
b
y
p
ar
ti
ci
p
an
ts
as
p
re
ve
n
ti
n
g
w
ill
in
gn
es
s
to
u
se
Pr
EP
w
er
e:
si
d
e
ef
fe
ct
s
(6
0.
8%
),
lo
w
se
lf
-
ri
sk
as
se
ss
m
en
t
(5
4.
2%
),
p
ri
va
cy
an
d
co
n
fi
d
en
ti
al
it
y
(4
1.
6%
),
th
e
p
er
ce
p
ti
o
n
th
at
Pr
EP
is
n
o
t
10
0%
ef
fe
ct
iv
e
(3
8.
3%
),
co
st
(2
8.
7%
),
in
co
n
ve
n
ie
n
ce
o
f
ta
ki
n
g
d
ai
ly
m
ed
ic
at
io
n
(6
8.
7%
),
an
d
re
p
o
rt
in
g
th
at
ri
sk
b
eh
av
io
rs
w
er
e
n
o
t
h
ap
p
en
in
g
d
ai
ly
(5
9%
).
Yi S et al. Journal of the International AIDS Society 2017, 20:21580
http://www.jiasociety.org/index.php/jias/article/view/21580 | http://dx.doi.org/10.7448/IAS.20.1.21580
9
Ta
b
le
2.
(C
on
ti
nu
ed
)
A
u
th
o
r,
ye
ar
C
o
u
n
tr
y
an
d
se
tt
in
g
D
es
ig
n
Sa
m
p
le
si
ze
P
ar
ti
ci
p
an
ts
’
ch
ar
ac
te
ri
st
ic
s
A
w
ar
en
es
s
W
ill
in
gn
es
s
to
u
se
Fa
ct
o
rs
as
so
ci
at
ed
w
it
h
w
ill
in
gn
es
s
to
u
se
Ya
n
g
et
al
.,
20
12
C
h
ia
n
g
M
ai
,
Th
ai
la
n
d
.
Su
rv
ey
.
13
1
M
SM
λ
M
ea
n
ag
e=
23
.7
;
ra
n
ge
18
–4
9
ye
ar
s.
μ
13
%
se
lf
-i
d
en
ti
fi
ed
as
h
et
er
o
se
xu
al
,
16
%
as
b
is
ex
u
al
an
d
71
%
as
ga
y.
66
%
aw
ar
e
o
f
Pr
EP
.
41
%
w
ill
in
g
to
u
se
Pr
EP
.ν
W
ill
in
gn
es
s
to
u
se
Pr
EP
am
o
n
g
M
SM
w
as
as
so
ci
at
ed
w
it
h
h
av
in
g
ze
ro
re
gu
la
r
p
ar
tn
er
s
in
th
e
p
re
ce
d
in
g
6
m
o
n
th
s
vs
.
o
n
e
o
r
m
o
re
p
ar
tn
er
s
(O
R
:
2.
25
;
95
%
C
I=
1.
09
–5
.1
1,
p=
0.
04
);
re
gu
la
rl
y
p
la
n
n
ed
se
x
vs
.
u
n
p
la
n
n
ed
se
x
(O
R
:2
.8
3;
95
%
C
I=
1.
12
–7
.1
2,
p=
0.
01
);
in
fr
eq
u
en
t
se
x
(o
n
ce
p
er
m
o
n
th
o
r
le
ss
)
vs
.
tw
o
o
r
m
o
re
se
xu
al
en
co
u
n
te
rs
p
er
m
o
n
th
(O
R
:2
.3
6;
p=
0.
02
);
a
lif
et
im
e
h
is
to
ry
o
f
ST
Is
vs
.
n
o
h
is
to
ry
o
f
ST
Is
(O
R
3.
78
,
95
%
C
I=
1.
42
–1
0.
47
,
p<
0.
01
);
ag
e
25
ye
ar
s
o
r
o
ld
er
vs
.a
ge
le
ss
th
an
25
ye
ar
s
(O
R
:2
.3
0;
95
%
C
I=
1.
10
–4
.7
9,
p=
0.
02
);
an
d
b
ei
n
g
“v
er
y
co
n
fi
d
en
t”
in
th
e
ab
ili
ty
to
ta
ke
d
ai
ly
,
o
ra
l
m
ed
ic
in
es
fo
r
1
ye
ar
vs
.
n
o
t
b
ei
n
g
“v
er
y
co
n
fi
d
en
t”
(O
R
:2
.6
3;
95
%
C
I=
1.
12
–6
.2
4,
p=
0.
01
).
In
co
n
tr
as
t,
w
ill
in
gn
es
s
to
u
se
w
as
n
o
t
as
so
ci
at
ed
w
it
h
a
lif
et
im
e
h
is
to
ry
o
f
H
IV
te
st
in
g
vs
.
n
o
h
is
to
ry
o
f
H
IV
te
st
in
g
(O
R
:1
.9
5;
95
%
C
I=
0.
89
–4
.2
9,
p=
0.
07
)
o
r
re
ce
p
ti
ve
an
al
se
x
p
o
si
ti
o
n
in
g
vs
.
in
se
rt
iv
e
o
r
ve
rs
at
ile
p
o
si
ti
o
n
in
g
(O
R
:0
.4
7;
95
%
C
I=
0.
17
–
1.
19
,
p=
0.
08
)
Zh
an
g
et
al
.,
20
13
C
h
o
n
gq
in
g,
G
u
an
gx
i,
an
d
Si
ch
u
an
,
C
h
in
a.
Su
rv
ey
.
14
02
M
SM
ο
A
ge
ra
n
ge
=1
8–
74
ye
ar
s.
18
–2
4
ye
ar
s
co
m
p
ri
se
d
41
.5
%
o
f
th
e
sa
m
p
le
.
M
aj
o
ri
ty
(7
5.
1%
)
re
si
d
ed
in
u
rb
an
ar
ea
s.
70
%
se
lf
-
id
en
ti
fi
ed
as
h
o
m
o
se
xu
al
an
d
21
%
as
b
is
ex
u
al
.
22
%
w
er
e
aw
ar
e
o
f
Pr
EP
64
%
w
er
e
w
ill
in
g
to
u
se
Pr
EP
if
sa
fe
an
d
ef
fe
ct
iv
e.
Pr
o
p
o
rt
io
n
w
ill
in
g
to
u
se
Pr
EP
in
cr
ea
se
d
to
71
%
if
it
w
er
e
to
b
e
m
ad
e
fr
ee
,a
n
d
to
77
%
if
it
w
er
e
fr
ee
an
d
h
ad
b
ee
n
u
se
d
b
y
p
eo
p
le
kn
o
w
n
to
p
ar
ti
ci
p
an
ts
.
H
o
w
ev
er
,
o
n
ly
30
%
an
d
37
%
w
er
e
w
ill
in
g
to
u
se
it
if
it
h
ad
to
b
e
ta
ke
n
o
n
ce
d
ai
ly
o
r
a
w
ee
kl
y
re
sp
ec
ti
ve
ly
.
W
ill
in
gn
es
s
to
u
se
Pr
EP
w
as
as
so
ci
at
ed
w
it
h
lo
w
er
ed
u
ca
ti
o
n
u
p
to
m
id
d
le
sc
h
o
o
l
co
m
p
ar
ed
to
th
o
se
w
it
h
co
lle
ge
ed
u
ca
ti
o
n
an
d
ab
o
ve
(6
8.
4%
vs
59
.5
%
;
p
=<
0.
00
1)
,
m
ar
ri
ed
m
ar
it
al
st
at
u
s
co
m
p
ar
ed
to
n
ev
er
m
ar
ri
ed
(6
9.
7%
vs
62
.4
%
;
p=
0.
03
5)
;
m
o
d
er
at
e
(1
00
0-
30
00
)
m
o
n
th
ly
in
co
m
e
(c
o
m
p
ar
ed
to
lo
w
er
ea
rn
in
gs
o
f
<1
00
0;
(p
=0
.0
13
)
b
u
t
n
o
t
co
m
p
ar
ed
to
h
ig
h
m
o
n
th
ly
in
co
m
e
o
f
>3
00
0
(p
=0
.1
09
);
an
d
ST
I
h
is
to
ry
co
m
p
ar
ed
to
th
o
se
w
it
h
o
u
t
ST
I
h
is
to
ry
(7
1.
9%
vs
62
.6
%
;
p=
0.
02
7)
.
Pa
rt
ic
ip
an
ts
w
h
o
d
id
n
o
t
o
r
ra
re
ly
fo
u
n
d
se
xu
al
p
ar
tn
er
s
o
n
th
e
in
te
rn
et
w
er
e
m
o
re
lik
el
y
to
b
e
w
ill
in
g
to
u
se
Pr
EP
co
m
p
ar
ed
w
it
h
h
ig
h
er
ri
sk
p
ar
ti
ci
p
an
ts
,
w
h
o
o
ft
en
o
r
so
m
et
im
es
fo
u
n
d
se
xu
al
p
ar
tn
er
s
o
n
th
e
in
te
rn
et
.
W
ill
in
gn
es
s
to
u
se
w
as
n
o
t
as
so
ci
at
ed
w
it
h
ag
e
o
r
re
si
d
en
ce
o
r
se
xu
al
id
en
ti
ty
.
Yi S et al. Journal of the International AIDS Society 2017, 20:21580
http://www.jiasociety.org/index.php/jias/article/view/21580 | http://dx.doi.org/10.7448/IAS.20.1.21580
10
Ta
b
le
2.
(C
on
ti
nu
ed
)
A
u
th
o
r,
ye
ar
C
o
u
n
tr
y
an
d
se
tt
in
g
D
es
ig
n
Sa
m
p
le
si
ze
P
ar
ti
ci
p
an
ts
’
ch
ar
ac
te
ri
st
ic
s
A
w
ar
en
es
s
W
ill
in
gn
es
s
to
u
se
Fa
ct
o
rs
as
so
ci
at
ed
w
it
h
w
ill
in
gn
es
s
to
u
se
Zh
o
u
et
al
.,
20
12
B
ei
jin
g,
C
h
in
a.
Su
rv
ey
.
15
2
M
SM
π
A
ge
ra
n
ge
=1
8–
61
ye
ar
s.
84
.9
%
se
lf
-i
d
en
ti
fi
ed
as
h
o
m
o
se
xu
al
an
d
15
.1
%
as
b
is
ex
u
al
.
11
.2
%
aw
ar
e
o
f
Pr
EP
.
67
.8
%
w
er
e
w
ill
in
g
to
‘d
ef
in
it
el
y’
o
r
‘p
ro
b
ab
ly
’
ta
ke
Pr
EP
if
av
ai
la
b
le
.
W
ill
in
gn
es
s
to
u
se
Pr
EP
w
as
as
so
ci
at
ed
w
it
h
yo
u
n
g
ag
e
<3
0
ye
ar
s
ve
rs
u
s
≥
30
ye
ar
s
(6
8.
8%
vs
.
83
.9
%
;
p
=0
.0
4)
.
W
ill
in
gn
es
s
to
u
se
Pr
EP
w
as
n
o
t
as
so
ci
at
ed
w
it
h
ye
ar
s
o
f
ed
u
ca
ti
o
n
(8
0%
am
o
n
g
th
o
se
w
it
h
<1
2
vs
68
.1
%
am
o
n
g
th
o
se
w
it
h
>1
2
ye
ar
o
f
ed
u
ca
ti
o
n
;
p=
0.
09
),
m
ar
it
al
st
at
u
s
(s
in
gl
e/
d
iv
o
rc
ed
/
w
id
o
w
ed
ve
rs
u
s
m
ar
ri
ed
/c
o
h
ab
it
in
g
[7
3.
1%
vs
77
.1
%
;
p
=0
.6
0)
,
lo
ca
l
B
ei
jin
g
re
si
d
en
ce
ve
rs
u
s
n
o
n
-B
ei
jin
g
re
si
d
en
ce
(6
3.
3%
vs
77
.1
%
;
p
=0
.1
3)
,
lo
w
er
m
o
n
th
ly
in
co
m
e
(R
M
B
)
<2
00
0
ve
rs
u
s
>2
00
0
(7
7.
1%
vs
72
%
;
p=
0.
47
;
b
is
ex
u
al
o
ri
en
ta
ti
o
n
ve
rs
u
s
h
o
m
o
se
xu
al
(7
3.
7%
vs
74
.7
%
;
p=
0.
89
],
o
r
p
re
vi
o
u
s
d
ia
gn
o
si
s
o
f
ST
D
in
th
e
p
as
t
6
m
o
n
th
s
ve
rs
u
s
n
o
su
ch
d
ia
gn
o
si
s
(8
8.
9%
vs
72
.4
%
;
p=
0.
15
.
Pa
rt
ic
ip
an
ts
ex
p
re
ss
ed
w
o
rr
y
ab
o
u
t
si
d
e
ef
fe
ct
s
(6
3.
8%
),
la
ck
o
f
p
re
ve
n
ti
o
n
ef
fi
ca
cy
in
Pr
EP
(4
4.
1%
),
d
ie
t
an
d
sl
ee
p
d
is
ru
p
ti
o
n
b
y
Pr
EP
(4
4.
7%
),
d
ev
el
o
p
m
en
t
o
f
re
si
st
an
ce
fr
o
m
Pr
EP
(2
1.
7%
),
b
ei
n
g
tr
ea
te
d
as
an
A
ID
S
p
at
ie
n
t
b
y
p
eo
p
le
(2
0.
1%
),
b
ei
n
g
re
fu
se
d
se
x
b
y
m
al
e
p
ar
tn
er
s
af
te
r
u
si
n
g
A
R
V
d
ru
gs
(1
4.
5%
)
o
r
n
o
t
b
ei
n
g
ab
le
to
af
fo
rd
A
R
V
d
ru
gs
(2
6.
3%
).
α
To
ta
l
p
ar
ti
ci
p
an
ts
in
th
is
st
u
d
y
w
er
e
37
48
,
an
d
w
er
e
fr
o
m
14
5
co
u
n
tr
ie
s
gl
o
b
al
ly
,
in
cl
u
d
in
g
A
si
a
(2
6%
),
C
ar
ib
b
ea
n
(2
%
),
Ea
st
er
n
Eu
ro
p
e
an
d
C
en
tr
al
A
si
a
(1
7%
),
La
ti
n
A
m
er
ic
a
56
7
(1
5%
),
M
id
d
le
Ea
st
an
d
N
o
rt
h
A
fr
ic
a
(2
%
),
O
ce
an
ia
(6
%
),
su
b
-S
ah
ar
an
A
fr
ic
a
(5
%
),
an
d
w
es
te
rn
an
d
N
o
rt
h
er
n
Eu
ro
p
e
an
d
N
o
rt
h
A
m
er
ic
a
(2
6%
).
A
w
ar
en
es
s
an
d
w
ill
in
gn
es
s
to
u
se
d
at
a
re
p
o
rt
ed
h
er
e
re
la
te
to
27
74
LM
IC
p
ar
ti
ci
p
an
ts
o
n
ly
;
gl
o
b
al
aw
ar
en
es
s
an
d
w
ill
in
gn
es
s
to
u
se
Pr
EP
w
er
e
72
%
an
d
82
%
,
re
sp
ec
ti
ve
ly
.
β
Pa
rt
ic
ip
an
ts
in
cl
u
d
ed
ga
y
m
en
,
o
th
er
m
en
w
h
o
h
av
e
se
x
w
it
h
m
en
an
d
tr
an
sg
en
d
er
p
ar
ti
ci
p
an
ts
(G
M
T)
.
A
m
o
n
g
43
4
o
f
52
0
w
er
e
H
IV
u
n
d
ia
gn
o
se
d
G
M
T
an
d
17
%
(n
=
86
)
w
er
e
H
IV
p
o
si
ti
ve
.
χ
Th
e
o
ve
ra
ll
sa
m
p
le
w
as
17
90
,
w
h
ic
h
in
cl
u
d
ed
M
SM
,
FS
W
s,
ID
U
s
in
Pe
ru
,
U
kr
ai
n
e,
In
d
ia
,
Ke
n
ya
,
B
o
ts
w
an
a,
U
ga
n
d
a,
an
d
So
u
th
A
fr
ic
a.
H
o
w
ev
er
,
M
SM
(n
=
38
3)
w
er
e
sa
m
p
le
d
in
Pe
ru
,
In
d
ia
,
So
u
th
A
fr
ic
a.
δ
14
07
M
SM
w
er
e
ap
p
ro
ac
h
ed
,
b
u
t
o
n
ly
13
23
q
u
es
ti
o
n
n
ai
re
s
co
m
p
le
te
d
an
d
an
al
yz
ed
.
ε
Th
e
o
ve
ra
ll
sa
m
p
le
w
as
11
87
o
f
w
h
o
m
95
.3
%
w
er
e
m
al
e
an
d
4.
7%
w
er
e
tr
an
sg
en
d
er
p
ar
ti
ci
p
an
ts
.
ϕ
A
to
ta
l
o
f
2,
64
4
p
ar
ti
ci
p
an
ts
w
er
e
sc
re
en
ed
fr
o
m
w
h
o
m
th
e
99
0
w
er
e
in
cl
u
d
ed
.
γ
Th
is
w
as
an
ex
cl
u
si
ve
sa
m
p
le
o
f
M
SM
w
h
o
w
er
e
al
so
se
x
w
o
rk
er
s.
η
A
m
o
n
g
th
e
93
.7
%
(n
=
28
1)
H
IV
-n
eg
at
iv
e
in
d
iv
id
u
al
s
in
th
e
st
u
d
y.
ι
Pr
o
p
o
rt
io
n
o
f
M
SM
vs
.
TG
w
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n
o
t
st
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ed
.
φ
47
0
M
SM
to
o
k
p
ar
t
in
th
e
su
rv
ey
b
u
t
40
4
co
m
p
le
te
d
th
e
su
rv
ey
an
d
w
er
e
in
cl
u
d
ed
in
th
e
an
al
ys
is
.
κ
A
to
ta
l
o
f
88
7
M
SM
st
ar
te
d
to
fi
ll
q
u
es
ti
o
n
n
ai
re
,
b
u
t
o
n
ly
76
0
q
u
al
if
ie
d
q
u
es
ti
o
n
n
ai
re
s
w
er
e
an
al
yz
ed
.
λ
32
6
in
d
iv
id
u
al
s
co
m
p
le
te
d
th
e
sc
re
en
in
g
q
u
es
ti
o
n
n
ai
re
o
u
t
o
f
w
h
ic
h
23
8
M
SM
an
d
TG
w
er
e
el
ig
ib
le
an
d
co
m
p
le
te
d
th
e
su
rv
ey
(1
31
M
SM
an
d
10
7
TG
)
μ
M
ea
n
ag
e
re
p
o
rt
ed
h
er
e
is
th
at
o
f
M
SM
p
ar
ti
ci
p
an
ts
o
n
ly
.
ν
W
ill
in
gn
es
s
re
p
o
rt
ed
h
er
e
is
am
o
n
g
M
SM
p
ar
ti
ci
p
an
ts
,
an
d
ex
cl
u
d
es
tr
an
sg
en
d
er
p
ar
ti
ci
p
an
ts
.
ο
14
07
M
SM
w
er
e
re
cr
u
it
ed
,
b
u
t
14
02
co
m
p
le
te
d
th
e
q
u
es
ti
o
n
n
ai
re
s
an
d
w
er
e
an
al
yz
ed
in
th
e
st
u
d
y.
π
15
9
M
SM
w
er
e
en
ro
lle
d
,
b
u
t
o
n
ly
15
2
u
se
d
fo
r
an
al
ys
is
as
7
w
er
e
d
el
et
ed
fo
r
n
o
t
h
av
in
g
se
x
w
it
h
m
en
in
th
e
p
as
t
6
m
o
n
th
s.
FS
W
:
fe
m
al
e
se
x
w
o
rk
er
;
G
M
T:
ga
y,
m
en
w
h
o
h
av
e
se
x
w
it
h
m
en
an
d
tr
an
sg
en
d
er
;
H
IV
:
h
u
m
an
im
m
u
n
o
d
ef
ic
ie
n
cy
vi
ru
s;
M
SM
:
m
en
w
h
o
h
av
e
se
x
w
it
h
m
en
;
ID
U
:
in
je
ct
in
g
d
ru
g
u
se
r;
PE
P:
p
o
st
-
ex
p
o
su
re
p
ro
p
h
yl
ax
is
;
Ta
iw
an
$:
Ta
iw
an
d
o
lla
r;
Pr
EP
:
p
re
-e
xp
o
su
re
p
ro
p
h
yl
ax
is
;
R
M
B
:
R
en
M
in
B
i
(c
u
rr
en
cy
o
f
Pe
o
p
le
’s
R
ep
u
b
lic
o
f
C
h
in
a)
;
ST
I:
se
xu
al
ly
tr
an
sm
it
te
d
in
fe
ct
io
n
;
ST
D
:
se
xu
al
ly
tr
an
sm
it
te
d
d
is
ea
se
;
TG
:
tr
an
sg
en
d
er
.
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Ta
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3.
C
h
ar
ac
te
ri
st
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s
an
d
fi
n
d
in
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o
f
m
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ed
-m
et
h
o
d
s
st
u
d
ie
s
in
cl
u
d
ed
in
th
e
sy
st
em
at
ic
re
vi
ew
A
u
th
o
r,
ye
ar
C
o
u
n
tr
y
an
d
se
tt
in
g
D
es
ig
n
Sa
m
p
le
si
ze
P
ar
ti
ci
p
an
ts
’
ch
ar
ac
te
ri
st
ic
s
A
w
ar
en
es
s
W
ill
in
gn
es
s
to
u
se
Fa
ct
o
rs
as
so
ci
at
ed
w
it
h
w
ill
in
gn
es
s
to
u
se
G
al
ea
et
al
.
[5
0]
Li
m
a,
Pe
ru
M
ix
ed
m
et
h
o
d
s
(F
G
D
s
an
d
co
n
jo
in
t
an
al
ys
is
)
17
M
SM
.α
M
ea
n
ag
e
fo
r
M
SM
=
33
ye
ar
s
Li
tt
le
o
r
n
o
aw
ar
en
es
s
o
f
Pr
EP
Pa
rt
ic
ip
an
ts
w
er
e
su
p
p
o
rt
iv
e
o
f
u
si
n
g
Pr
EP
,
b
u
t
h
ad
va
ri
o
u
s
co
n
ce
rn
s
H
ig
h
o
u
t-
o
f-
p
o
ck
et
co
st
,
p
ar
ti
al
ef
fi
ca
cy
,
an
d
fe
ar
o
f
si
d
e
ef
fe
ct
s,
st
ig
m
a
an
d
d
is
cr
im
in
at
io
n
w
er
e
as
so
ci
at
ed
w
it
h
Pr
EP
u
se
,
w
h
ile
m
is
tr
u
st
o
f
h
ea
lt
h
-c
ar
e
p
ro
fe
ss
io
n
al
s
an
d
a
b
el
ie
f
th
at
Pr
EP
w
o
u
ld
re
su
lt
in
a
d
ec
re
as
e
in
co
n
d
o
m
u
se
w
er
e
co
n
ce
rn
s
fo
r
M
SM
.
Pa
rt
ic
ip
an
ts
p
re
fe
rr
ed
Pr
EP
p
ro
vi
d
ed
at
h
ea
lt
h
ca
re
ce
n
tr
es
as
o
p
p
o
se
d
to
p
h
ar
m
ac
ie
s,
d
u
e
to
co
st
.
Ka
ru
ga
et
al
.
[5
1]
Ki
su
m
u
,
Ke
n
ya
M
ix
ed
m
et
h
o
d
s.
80
M
SM
M
ed
ia
n
ag
e
=
24
.9
ye
ar
s.
68
.8
%
w
er
e
H
IV
n
eg
at
iv
e,
11
.8
%
w
er
e
se
x
w
o
rk
er
s,
an
d
49
.1
%
w
er
e
ex
cl
u
si
ve
ly
h
o
m
o
se
xu
al
Pr
ec
is
e
p
ro
p
o
rt
io
n
n
o
t
re
p
o
rt
ed
,
b
u
t
in
-d
ep
th
kn
o
w
le
d
ge
o
f
Pr
EP
w
as
n
o
te
d
to
b
e
lo
w
83
.3
%
w
er
e
w
ill
in
g
to
u
se
Pr
EP
if
m
ad
e
av
ai
la
b
le
.β
W
ill
in
gn
es
s
to
u
se
Pr
EP
w
as
as
so
ci
at
ed
w
it
h
se
xu
al
o
ri
en
ta
ti
o
n
,
b
ei
n
g
h
ig
h
er
am
o
n
g
b
is
ex
u
al
co
m
p
ar
ed
to
h
o
m
o
se
xu
al
(9
6.
2%
vs
.
74
.1
%
;
p
=
0.
02
5)
.
W
ill
in
gn
es
s
to
u
se
Pr
EP
w
as
n
o
t
as
so
ci
at
ed
w
it
h
ag
e
(p
=
0.
61
6)
,
o
r
u
n
iv
er
si
ty
co
m
p
ar
ed
to
se
co
n
d
ar
y
ed
u
ca
ti
o
n
(8
1.
2%
vs
.
89
.5
%
;
p
=
0.
47
0)
,
o
r
m
ar
it
al
st
at
u
s
(p
=
0.
15
7)
.
St
ig
m
a,
ge
n
er
al
d
is
lik
e
o
f
ta
ki
n
g
m
ed
ic
in
es
,
u
n
ce
rt
ai
n
ty
o
ve
r
Pr
EP
ef
fe
ct
iv
en
es
s,
co
st
,
an
d
a
la
ck
o
f
in
fo
rm
at
io
n
w
er
e
re
p
o
rt
ed
as
in
fl
u
en
ci
n
g
w
ill
in
gn
es
s
to
u
se
Pr
EP
fr
o
m
q
u
al
it
at
iv
e
in
te
rv
ie
w
s.
α
Th
e
o
ve
ra
ll
sa
m
p
le
w
as
45
in
cl
u
d
in
g
15
FS
W
,
13
TG
,
an
d
17
M
SM
.
Fi
gu
re
s
fo
r
ea
ch
co
u
n
tr
y
w
er
e
re
p
o
rt
ed
se
p
ar
at
el
y
b
u
t
h
av
e
b
ee
n
av
er
ag
ed
h
er
e.
β
W
ill
in
gn
es
s
re
p
o
rt
ed
is
am
o
n
g
th
e
55
H
IV
-n
eg
at
iv
e
M
SM
.
FS
W
:
fe
m
al
e
se
x
w
o
rk
er
;
FG
D
s:
fo
cu
s
gr
o
u
p
d
is
cu
ss
io
n
s;
M
SM
:
m
en
w
h
o
h
av
e
se
x
w
it
h
m
en
;
Pr
EP
:
p
re
-e
xp
o
su
re
p
ro
p
h
yl
ax
is
;
TG
:
tr
an
sg
en
d
er
.
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Ta
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at
ic
re
vi
ew
A
u
th
o
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ye
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o
u
n
tr
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se
tt
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m
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le
si
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P
ar
ti
ci
p
an
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ch
ar
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te
ri
st
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w
ar
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W
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es
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to
u
se
Fa
ct
o
rs
as
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ci
at
ed
w
it
h
w
ill
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gn
es
s
to
u
se
B
o
u
rn
e
et
al
.
[3
2]
Ku
al
a
Lu
m
p
u
r,
M
al
ay
si
a.
Q
u
al
it
at
iv
e
18
M
SM
.
N
o
t
re
p
o
rt
ed
,
b
u
t
el
ig
ib
ili
ty
w
as
≥
18
ye
ar
s
o
f
ag
e.
N
o
t
re
p
o
rt
ed
.
M
o
st
M
SM
w
er
e
w
ill
in
g
to
u
se
Pr
EP
b
u
t
co
n
ce
rn
ed
ab
o
u
t
a
ra
n
ge
o
f
b
ar
ri
er
s.
Pa
rt
ic
ip
an
ts
w
o
u
ld
co
n
si
d
er
Pr
EP
in
fu
tu
re
if
th
ey
h
ad
h
ig
h
er
n
u
m
b
er
o
f
co
n
cu
rr
en
t
se
xu
al
p
ar
tn
er
s
an
d
if
Pr
EP
w
er
e
fr
ee
o
r
co
st
a
m
ax
im
u
m
o
f
R
M
50
–2
00
(U
SD
12
–4
9)
p
er
u
se
r
p
er
m
o
n
th
.
B
ar
ri
er
s
in
cl
u
d
ed
p
o
te
n
ti
al
si
d
e
ef
fe
ct
s,
an
ti
ci
p
at
ed
la
ck
o
f
d
is
ci
p
lin
e
to
ta
ke
Pr
EP
d
ai
ly
,
co
n
fi
d
en
ti
al
it
y
an
d
d
at
a
p
ro
te
ct
io
n
co
n
ce
rn
s,
fe
ar
o
f
st
ig
m
a
an
d
b
ei
n
g
p
er
ce
iv
ed
as
h
av
in
g
ri
sk
ie
r
b
eh
av
io
u
rs
su
ch
as
ba
re
ba
ck
in
g
o
r
‘r
aw
se
x’
b
y
n
o
n
-P
rE
P
u
si
n
g
p
ee
rs
.
Th
e
ph
ys
ic
al
b
ar
ri
er
o
f
co
n
d
o
m
s
w
as
p
re
fe
ra
b
le
to
Pr
EP
w
h
ic
h
ca
n
’t
b
e
se
en
o
r
fe
lt
.
Pa
rt
ic
ip
an
ts
fe
lt
th
at
Pr
EP
m
ay
n
o
t
b
e
n
ee
d
ed
in
m
o
n
o
ga
m
o
u
s
re
la
ti
o
n
sh
ip
s
as
u
se
o
f
co
n
d
o
m
s
w
o
u
ld
b
e
su
ff
ic
ie
n
t.
C
h
ak
ra
p
an
i
et
al
.
[5
2]
C
h
en
n
ai
an
d
M
u
m
b
ai
,
In
d
ia
.
Q
u
al
it
at
iv
e
61
M
SM
an
d
10
ke
y
in
fo
rm
an
ts
α
.
21
.3
%
w
er
e
b
is
ex
u
al
an
d
m
ea
n
ag
e
=
26
.1
.
N
o
n
e
o
f
th
e
p
ar
ti
ci
p
an
ts
w
er
e
aw
ar
e
55
.7
%
w
o
u
ld
u
se
Pr
EP
if
av
ai
la
b
le
St
ig
m
a,
sh
am
e,
la
ck
o
f
tr
u
st
,
co
st
o
f
Pr
EP
,
fa
ke
p
ill
s,
an
d
fe
ar
o
f
si
d
e
ef
fe
ct
s
w
er
e
b
ar
ri
er
s.
M
o
ti
va
to
rs
in
cl
u
d
ed
p
ea
ce
o
f
m
in
d
w
h
en
co
n
d
o
m
s
b
re
ak
/s
lip
,
‘a
d
d
it
io
n
al
p
ro
te
ct
io
n
’
in
ca
se
co
n
d
o
m
b
re
ak
s,
d
es
ir
e
to
h
av
e
sa
fe
se
x
w
it
h
H
IV
-p
o
si
ti
ve
st
ea
d
y
p
ar
tn
er
s,
an
d
ab
ili
ty
to
ta
ke
Pr
EP
d
is
cr
ee
tl
y.
α
Ke
y
in
fo
rm
an
ts
(n
=
10
)
in
cl
u
d
ed
co
m
m
u
n
it
y
le
ad
er
s
an
d
h
ea
lt
h
ca
re
p
ro
vi
d
er
s.
M
SM
:
m
en
w
h
o
h
av
e
se
x
w
it
h
m
en
;
Pr
EP
:
p
re
-e
xp
o
su
re
p
ro
p
h
yl
ax
is
;
R
M
:
M
al
ay
si
a
R
in
gg
it
;
U
SD
:
U
SA
d
o
lla
r.
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serodiscordant couples, and young women in Ukraine,
India, and other African countries. Studies by Peinado
et al. [42], Yang et al. [47], and Hoagland et al. [39] included
MSM and TG populations. These studies segregated the
results by gender identity, and for the purpose of this
review, only data related from MSM in these studies were
considered. However, the 2016 study by Draper et al. [37]
included MSM and TG participants, who were not fully
segregated.
Given the relevance of PrEP for HIV prevention, most
studies included HIV-negative status as an eligibility criter-
ion. However, in the study by Karuga et al. [51], only 68%
were HIV negative, because recruitment involved all MSM
who were presenting for HIV testing, but only HIV-negative
participants were asked about their willingness to use PrEP.
Likewise, 46.8%, 18%, and 17% of initial participants in the
studies by Hoagland et al. [39], Ayala et al. [35], and Draper
et al. [37] were HIV positive, respectively. Similarly, in these
studies, willingness data were generated from HIV-negative
participants. The Thai study by Ding et al. [36] and the
Malaysian study by Lim et al. [31] found that a small propor-
tion of their participants were already using PrEP (2.5% and
<1%, respectively). Finally, the profile of participants was
also influenced by the recruitment strategies of the included
studies, including eligibility criteria. While most studies
recruited MSM older than 18 years, two studies had lower
age eligibility criteria of 15 years [41] or 16 years [33].
Bias assessment
Included studies had multiple sources of bias resulting from
confounding, recruitment, non-response, social desirability,
and attrition bias (supplemental file 3).
Confounding: All of the quantitative studies were cross-
sectional in design and had high potential for bias and
confounding. All studies reported hypothetical likelihood
of using PrEP, which could change once PrEP is provided.
Recruitment bias: The risk of recruitment bias was sig-
nificant in a number of studies, based on the methods and
settings where recruitment took place. The study by Ayala
et al. [35] included MSM participants from 145 countries
globally, including Asia (26%), the Caribbean (2%), Eastern
Europe and Central Asia (17%), Latin America (15%), Middle
East and North Africa (2%), Oceania (6%), sub-Saharan
Africa (5%), and western and Northern Europe and North
America (26%). In this study [35], awareness and willing-
ness to use data were segregated by geographic region.
However, overall correlation statistics were not, and there-
fore participants from high-income settings may affect the
reported correlation statistics. In the Indian study by
Chakrapani et al. [52], participants were recruited exclu-
sively through a community-based organization, an
approach that may have excluded MSM who did not have
contact with community-based HIV services. Sineath et al.
[43] recruited a convenience sample of Thai MSM exclu-
sively through online methods, which excluded those who
did not have access to internet.
The studies by Lim et al. [31], Bourne et al. [32], and
Jackson et al. [53] expanded their online-based recruitment
to include recruitment through local non-governmental
organizations, which may have facilitated inclusion of dif-
ferent profiles of MSM. A number of studies recruited
specifically from sites which were thought to be frequented
by high-risk MSM, including from entertainment venues in
Thailand [33,47], gay community events in China [53], and
beauty salons in Peru [50]. Although appropriate for identi-
fying MSM who require PrEP, these strategies may exclude
other MSM, for example those who are not living openly as
MSM. A number of studies in Thailand [43], Malaysia
[31,32], Kenya [51], and China [46], among others, started
off by recruiting MSM and then screened them for eligibil-
ity based on age, HIV status, and availability and interest to
participate in interviews, among other criteria, thereby
limiting generalizability of findings to wider MSM popula-
tions. In addition, recruitment from rural areas across all
studies was limited.
Attrition and non-response bias: The studies by Xue et al.
[46], Sineath et al. [43], Zhang et al. [48], and He et al. [38]
reported instances of non-responses or incompletely filled
questionnaires, which introduced response bias and may
limit generalizability.
Social desirability bias: Most of the measures reported in
the included studies were self-reported, and therefore
were prone to social desirability bias, especially self-
reported sexual behaviours. Because of a social desire for
positive self-presentation, willingness to use PrEP may have
been over-reported by some participants in Peru who saw
its use as responsible behaviour [50] while it could have
been under-reported by other participants in Malaysia,
India, Peru, and Thailand who thought it may be perceived
it as a sign of promiscuity [32,33,50,52]. The potential for
social desirability bias may have been mitigated by the use
of anonymous online data collection methods in the studies
by Sineath et al. [43], Lim et al. [31], and Ayala et al. [35],
while being particularly accentuated in four studies by
Bourne et al. [32], Chakrapani et al. [52], Karuga et al.
[51], and Galea et al. [50], which involved face-to-face
focus group discussions with peers. The two studies by
Chakrapani et al. [52] and Karuga et al. [51] also involved
in-depth interviews in addition to focus group discussions.
Researcher bias: The four studies that reported qualita-
tive findings lacked clarity around reflexivity. They con-
tained limited documentation of interview dynamics,
emotions, interactions, or beliefs of the researchers as
recommended [54], especially when dealing with sensitive
topics [55]. Although absence of this information may have
been occasioned by word count limitations, it limited our
analysis of the researchers’ influence on the research con-
duct and reported findings, which is an essential element of
evaluating qualitative research [25].
Description of PrEP
The included studies used consistent definitions of PrEP and
most explored oral PrEP except for the Peruvian study con-
ducted by Peinado et al. [42], which explored both oral and
rectal PrEP. However, findings in this study were segregated
by route of administration. Most studies provided a
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definition of PrEP to participants and emphasized the need
to adhere to medications as part of the definition.
In addition, four studies [33,34,41,50] explored participants’
preferences regarding themost desirable formulations of PrEP,
such as injectable or oral or lubricant forms. However, these
results did not affect the data reported in this review regarding
willingness to use oral PrEP, as data were segregated.
Definitions and general information regarding PrEP were
provided by researchers or data collectors who were facil-
itating interviews, focus group discussions [32,49,50,52], or
face-to-face quantitative questionnaires [33,34,47]. In other
studies, this information was provided online as part of the
study [31,35]. In one Indian study, explanation of PrEP was
facilitated by pictorial cards [52], while in several other
studies [33,34,49,52], PrEP definitions were provided in
both English and local languages to aid its understanding.
At least three studies [31,32,50] made explicit attempts to
differentiate PrEP from post-exposure prophylaxis (PEP) in
their definitions of PrEP to participants, and in rare cases
[52], data collectors were provided with fact sheets to
respond consistently to participants’ queries.
Nature of outcomes reported
Of the outcomes of interest to this review, the most
reported outcome was willingness to use. All quantitative
studies reported either proportions of participants who
were aware of or willing to use PrEP, or both, with a
number of them examining willingness to use PrEP in dif-
ferent situations related to efficacy, cost, knowledge of
partners, condom use, and stigma [31,33,34,40,41,49].
Two qualitative [32,52] and two mixed-methods studies
[50,51] explored perceptions and perceived barriers and
facilitators of willingness to use PrEP, in relation to relation-
ships, sex, PrEP information and education, cost, ways and
venues to access PrEP, risk perception, ideal nature of PrEP,
perceived effectiveness, side effects, and adherence issues.
Four studies [35,42,47,52] exploring willingness to use
described this outcome as acceptability, even though they
explored theoretical use of PrEP if it were made available.
This information was abstracted and reported as willingness
to use. Because this review excluded trials in which PrEP
was being assessed, it excluded actual acceptability in
which PrEP was provided as part of the study. In one
study by Ding et al. [36], participants were assessed for
willingness to use PrEP and were subsequently offered it.
However, although the study noted the proportion of parti-
cipants that eventually took up the PrEP (20.5% changed
their minds), this review abstracted the initial willingness to
use data, rather than the acceptance data. Nevertheless, as
noted above, the study by Ding et al. [36] and that by Lim
et al. [31] incidentally found that small proportions of
participants (2.5% and <1%, respectively) were already
accessing and using PrEP at the time of the study.
Awareness of PrEP
Of the 14 studies reporting levels of awareness, 13 pro-
vided quantitative proportions of participants who were
aware of PrEP. All studies reporting awareness used a
simple binary question asking participants whether they
were aware (or had heard) of PrEP, which was a consistent
measure of awareness across studies. Most studies that
explored awareness found a lack of awareness of PrEP
among participants. With the exception of four studies by
Hoagland et al. in Brazil [39], Yang et al. in Thailand [47],
Ayala et al. [35], and Xue et al. in China [46] that reported
awareness of 61.3%, 66.0%, 69.8%, and 72.8% respectively,
most studies reported much lower awareness of PrEP ran-
ging from 5.0% in Myanmar [37], 7.0% in Thailand [43],
11.2% in China [49], 19.1%, 19.7%, 22%, and 31.4% in China
[38,44,45,48], and 44.0% in Malaysia [31]. In the Peruvian
study by Galea et al. [50], participants had little or no
awareness of PrEP. In addition, the Indian study by
Chakrapani et al. [52] reported that none of the partici-
pants in their study were aware of PrEP prior to the study.
The proportions were highly heterogeneous (Q statis-
tic = 2898, I2 = 99.5; (95% CI: 99.5–99.6), p < 0.001).
Meta-analysis of the 13 studies that reported quantitative
data of proportions of MSM who were aware of PrEP found
that the pooled estimate of awareness among MSM was
29.7% (95% CI: 16.9–44.3) (Figure 3).
Besides overall awareness, few studies explored factors
that were associated with awareness of PrEP. Older age in
Brazil [39], more years of education in Brazil and Thailand
[39,43], urban residence in China [45], frequent use of
internet as a source of information in China [45], employ-
ment in Thailand [43], and non-local ethnicity in Thailand
[43] were associated with higher levels of awareness. Two
studies from Brazil [39] and China [45] reported conflicting
results regarding the association between PrEP awareness
and gender identity (gay versus TG or bisexual) or a recent
STI diagnosis. Marital status was not associated with PrEP
awareness in China [45].
However, the reported awareness did not necessarily
reflect an accurate understanding of PrEP. Three studies
checked whether the self-reported understanding of PrEP
was accurate. In India, four participants who initially
reported that they had heard of PrEP were later found to
have mistaken PEP for PrEP [52]. In a Chinese study by Xia
et al. [45], 19.1% of participants were aware of PrEP.
However, when their self-reported understanding of PrEP
was assessed, only around half of them (9.5%) had what
could be considered an accurate understanding. Two stu-
dies [35,46] made a distinction between participants who
were aware of the basics and those who fully understood
PrEP and found that roughly half of participants who
reported being aware of it had just a basic understanding.
In addition, some studies [33,34,50,52] provided informa-
tion and definitions of PrEP before the assessment of
awareness while others [32,49] defined it after assessment
of awareness but before assessment of willingness to use it,
which may have introduced varying potential for recall bias.
This was compounded by the fact that participants had
opportunities to ask clarification questions in studies that
utilized face to face data collection methods
[32,34,49,50,52], but did not have this opportunity in stu-
dies that used online methods exclusively [31,35,43].
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Nevertheless, four studies provided useful information
regarding sources of PrEP information, noting that partici-
pants may have heard of PrEP from the internet and print
media in Malaysia and China [31,45], friends in Thailand,
Malaysia, and China [31,45,47], healthcare providers in
Thailand and Malaysia [31,47], or from previously publi-
cized clinical trials in Peru [50].
Willingness to use PrEP
Twenty studies assessed quantitative proportions of parti-
cipants who were willing to use PrEP, while two studies
reported qualitative assessment of willingness to use.
Quantitative studies reporting willingness to use PrEP
used a variety of scales and methods to derive the propor-
tion of participants who were willing to use PrEP. Most
studies [31,33–35,37,39–41,45,47,53], used different itera-
tions of ratings on Likert-like scales, while a few
[36,43,48,51] used simple binary measures. In general, pro-
portions of participants willing to use PrEP varied signifi-
cantly, ranging from a low proportion of 19.1% in China to a
high proportion of 96.2% in Peru. Six studies reported low
levels of willingness to use, in which less than half the
participants were willing to use PrEP. These included
19.1% and 32.1% in two Chinese studies [36,46], 36%,
39.2% to 49.2% and 41% in three Thai studies [33,43,47],
and 39.0% in Malaysia [31]. However, the majority of stu-
dies reported moderate-to-high levels of willingness to use
PrEP. In nine studies, 50–70% of participants were willing to
use PrEP, including 56.0% in Taiwan [40], 55.7% in India
[52], 62% in Myanmar [37], 63.0–91.9% in China
[44,48,49,53], and an average of 69.0% across India, Peru,
and South Africa in a multi-country study [34]. In five
studies, this proportion was >80%, and included 80.8%
among LMIC participants in the multi-country study by
Ayala et al. [35], 82.1% in Brazil [39], 83.3% in Kenya [51],
95.4% in Vietnam [41], and 96.2% in Peru [42]. As might be
expected, these studies were highly heterogeneous (Q sta-
tistic = 3305, I2 = 99.4; (95% CI: 99.3–99.5, p < 0.001). Meta-
analysis of these studies found that 64.4% (95% CI: 53.3–
74.8) of MSM were willing to use PrEP (Figure 4).
Factors associated with willingness to use PrEP
Table 5 illustrates the range of factors influencing MSM’s
willingness to use PrEP documented in the included studies.
These factors, which could potentially prevent or facilitate
participants’ willingness to use of PrEP, conceptually fell
into different categories within the individual, social
(including partners, families, and communities) and struc-
tural domains (health systems and legal factors).
Individual factors
Awareness, knowledge, and information about PrEP
Awareness is an important pre-requisite of utilization of
health products, especially new interventions such as
PrEP. In most studies, initial awareness of PrEP was low.
However, once participants became aware of PrEP, most
expressed interest in using it. For instance, although none
of the participants were aware of PrEP in an Indian study by
Chakrapani et al. [52], 55.7% of them reported willing to
use it once they were informed of the concept of PrEP, its
benefits for HIV prevention, and side effects. In Myanmar
[37], 5.0% of the participants were initially aware, but
62.0% were willing to use it once they were informed
about it. In China [48], awareness was 22.0% while will-
ingness to use after introduction of the concept to the
participants was 64.0%. In another Chinese study by Xia
et al. [45], 19.1% were initially aware, but 71.3% were
Figure 3. Pooled estimate of awareness of PrEP among MSM in low- and middle-income countries.
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willing to use it once they became aware of it, and in yet
another Chinese study [49], 11.2% were aware of PrEP,
while 67.8% were willing to “definitely” or “probably”
take PrEP if available. The same pattern was observed in
Thailand [43], where 7.0% were aware and 36.0% were
willing to use after PrEP was described, and in Brazil
Figure 4. Pooled estimate of willingness to use PrEP among MSM in low- and middle-income countries.
Table 5. Factors affecting willingness to use HIV pre-exposure prophylaxis (PrEP) among men who have sex with men in low-
and middle-income countries
Domains Barriers Source study Facilitating factors Source study
Individual
factors
Lack of PrEP information and
awareness.
[37,39,43,45,48,50,52] PrEP awareness and motivation to stay
HIV negative.
[32,51,52]
Concerns/doubts about PrEP
effectiveness.
[31,32,43,44,49,52] Perception that PrEP is 100% effective. [50,51]
Fear of side effects. [31–33,44,49,51,52] Need for intimacy and romance with a
partner who is HIV positive.
[52]
Low-risk perception among those at
high risk
[32,46] Multiple anal sex partners or history of STI
or PEP.
[36,37,40,48]
Need to take medicines frequently/
daily.
[31,32,43,51] Convenient dosing (injectable, monthly, or
weekly).
[33,50]
Competing preference for condoms
(which can also be physically felt
during sex).
[31,32,36] Peace of mind if condom breaks or slips
(PrEP as a second layer of protection).
[32,52]
Social factors Fear of HIV stigma (since ARVs are used
for treatment of HIV-positive people).
[49,51–53] Ability to take PrEP pill discretely. [52]
Stigma towards homosexual orientation [32,35,50,52] Desire to protect sexual partner [51]
PrEP stigma or embarrassment using
PrEP.
[31–33,35] Peer and partner support. [48–50,52]
Structural
factors
Perceived attitudes of healthcare staff. [50] Wide availability of PrEP (clinics,
community organizations, pharmacies,
internet, etc.)
[31,32,50,52]
Perceived lack of quality assurance. [52]
Perceived lack of data confidentiality. [32] Discrete packaging. [51]
Cost. [31,32,37,40,52] Free or heavily subsidized PrEP. [32,37,51]
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where 61.3% were aware and 82.1% were willing to use it
[39]. In the multi-country study by Ayala et al. [35], aware-
ness of PrEP was 69.8% while willingness to use it was
80.8% among participants from LMIC.
However, three studies were exceptions to this general
trend. In a Chinese study by Xue et al. [46], awareness was
72.8%, while willingness to use was much lower at 32.1%.
In another Chinese study by Yang et al. [47], 66.0% were
aware of PrEP, but 41.0% were willing to use it, while in the
Malaysian study by Lim et al. [31], 44.0% were aware, but
39.0% were willing to use it (Figure 5).
Motivation to stay healthy and HIV negative
Participants from Kenya identified provision of more informa-
tion on PrEP as a factor that would facilitate their uptake and
utilization of PrEP as they would have known of its preventive
benefits [51]. In this study, the need to stay HIV negative and
to protect their partners were common motivators for taking
PrEP. In a typical response, one participant in a Peruvian study
[50] elaborated his understanding and the reason he would
take PrEP as about caring for his own health:
‘I [would] take PrEP, I would say that it is my own
caring about myself, something which is only mine.’
This motivation regarding the protection of one’s own health
was still sufficient even if participants had to pay for it, as
explained by another MSM participant in the same study:
‘Yes, of course [I would pay for PrEP] . . . something
that says that at least I am paying some of my own
money for my health.’
Fear of side effects
The most frequently explored determinant of potential PrEP
use was perceived side effects. In most studies, such as in
India [52], Thailand [33], Myanmar [37], Malaysia [31,32],
Kenya [51], and China [44,49], participants had concerns
about side effects, which were generally non-specific. In a
study in China [49], 44.7% of MSM participants expressed
specific worries regarding the impact of PrEP on their diet
and sleep, while in Myanmar [37], participants were more
concerned about long-term use. In the Kenyan study [51],
and in response to whether he would use PrEP, one focus
group discussion participant said that: “I will not use it,
because I don’t know if it will cause some harm in my body.”
Although concerns regarding ARV side effects reduced
willingness to use PrEP in most studies, it did not eliminate
motivations to take it entirely. In Thailand [33], concern for
side effects reduced the proportion of those willing to use
PrEP. Before participants were informed about potential side
effects, 39.2% were definitely willing to use PrEP, but 24.6%
were still willing to take PrEP once they learnt about its
possible side effects. A similar pattern was observed in the
multi-country study by Eisingerich et al. [34] as shown in the
above Table 2. In Vietnam [41], the proportion willing to use
PrEP daily reduced from 95.4% to 56.7% given side effects.
Need to adhere to PrEP
Three studies reported the requirement to take PrEP fre-
quently as a barrier to future use of PrEP. In Thailand [43],
concerns were reported about the need for daily dose as a
potential barrier. In Kenya, participants singled out a general
dislike ofmedicine as a deterrent [51]. Participants inMalaysia
were aware of the need to adhere, but most admitted that
they may “lack the discipline to take PrEP on daily basis” [32].
In another Malaysian study [31], 8.3% of the 603 participants
who were not willing to use PrEP were worried about forget-
ting to take medication. Participants in the Thai study by
Wheelock et al. [33] suggested that monthly injection in the
arm could facilitate PrEP use by reducing the need for swal-
lowing daily pills. In response to the question about ideal
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Figure 5. Relationship between awareness and willingness to use PrEP in studies reporting both outcomes.
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characteristics of PrEP, oneMSM participant in a study in Peru
[50] responded by saying that:
‘If they ask me to choose, I’d rather have it weekly
or twice a week, by tablet, capsule, shot or what-
ever, it is far more likely than doing it daily.’
However, the preference for injections was not universal in
all studies. In the multi-country study by Eisingerich et al.
[34], Indian and Peruvian MSM preferred bimonthly injec-
tion in the buttocks, while South African MSM preferred
daily pills to injection in the arm. In Vietnam [41], 27.7% of
those who were willing to use PrEP preferred a lubricant to
a pill. In contrast to the above studies, however, the
Vietnamese study did not explore preferences regarding
injectable PrEP.
Risk perception
Psychological factors such as risk perception emerged as an
important determinant of willingness to use PrEP. On the
one hand, studies by Ding et al. [36] and Zhang et al. [48]
found that MSM who had more anal sexual partners and
those who had STIs were more willing to use PrEP. In
Myanmar [37], willingness to use PrEP was higher among
participants who had more than one regular partner
(adjusted odds ratio (AOR):2.94; 95% confidence interval
(CI) = 1.41–6.14) or more than five casual partners
(AOR:2.05; 95% CI = 1.06–3.99). In this study, MSM who
never or only occasionally used condoms with casual part-
ners were more likely to be willing to use PrEP (AOR: 2.02;
95% CI = 1.00–4.10) in Taiwan [40], willingness to use PrEP
was significantly associated with the previous receipt of HIV
PEP (AOR:3.02, 95% CI = 1.49–6.12, p = 0.002). On the
other hand, participants who perceived their risk of HIV
to be low were unlikely to use PrEP. In a Malaysian study by
Bourne et al. [32], some participants saw no need for PrEP
as they were in monogamous relationships in which they
used condoms, as they believed their risk was low. Several
of these MSM also expressed that they would consider PrEP
in the future if they would have a higher number of con-
current sexual partners. In another Malaysian study [31],
11.4% of the participants who were not willing to use PrEP
identified the fact that they always used a condom as a
reason why they would not need PrEP, implying that they
thought that their risk of HIV was low. In Taiwan, partici-
pants who had sought and used HIV non-occupational PEP
were significantly more likely to be willing to use PrEP [40].
In a Chinese study by Xue et al. [46], 54.2% of the partici-
pants did not want to use PrEP due to low self-risk assess-
ment. In that study, 59.0% of participants perceived that
“risk behaviors were not happening every day” and there-
fore they would not use PrEP. This sentiment was also
reported in a Peruvian study by Galea et al. [50], where a
participant expressed the following:
‘Well, if I am a person who has continuous [sexual]
relationships yes, I’d take it, but if I [didn’t], why
would I take it?’
However, participants’ perception of risk may not have
been accurate. This lack of accurate risk perception may
contribute to the paradoxical observation that participants
in a Chinese study [48] who did not or rarely found sexual
partners on the internet were more likely to be willing to
use PrEP compared with higher-risk participants, who often
or sometimes found sexual partners on the internet.
Demographic factors
Eleven studies examined the association between willing-
ness to use PrEP and a range of demographic factors. The
association between participants’ demographic characteris-
tics and willingness to use PrEP was generally inconsistent.
Older age was found to be associated with willingness to
use PrEP in two studies from China [36,49] and one study
from Thailand [47]. However, this association was not found
in studies in Kenya [51], Malaysia [31], Brazil [39], Taiwan
[40], or in another study from China [48]. While two
Chinese studies [45,48] suggested that willingness to use
was higher among married participants as compared to
unmarried, divorced, or widowed participants, three other
studies from China [36,49] and Kenya [51] did not find such
association. Several studies found that income [31,49] or
employment status [31,40] were not associated with will-
ingness to use PrEP [31]. In contrast, two Chinese studies
[48,53] found that participants with lower monthly incomes
were more willing to use it compared to those with higher
monthly incomes.
Although two studies from China and Kenya suggested
that bisexual participants were more likely to use PrEP
compared to participants who identified themselves as
homosexual [45,51], three studies in China [36,48,49] and
one study in Brazil [39] did not find such association.
Participants who had immigrated to the cities where the
studies were conducted were reported to be more willing
to use PrEP in Shanghai, China [36], but this association was
not found in another study in Beijing, China [49] or Kuala
Lumpur, Malaysia [31]. In addition, two studies examined
the impact of rural versus urban residency reported con-
trasting results [48,53]. In the multi-country study by Ayala
et al. [35], participants in LMIC expressed higher willingness
to use PrEP compared to those from high-income countries.
Local ethnicity was reported to be associated with willing-
ness to use PrEP in Malaysia [31], although this was not
commonly explored across other studies. One study
reported an association between willingness to use PrEP
and depressive symptoms among Chinese participants [53],
but no other study reported association with mental health
status. Overall, the evidence was inconsistent in regards to
demographic factors.
Uncertainty regarding the benefit of PrEP
Doubts regarding the benefit of PrEP were reported in
Thailand, Malaysia, and China [32,43,44,49,52]. In China,
44.1% of participants expressed worries that PrEP had no
prevention efficacy [49]. In Malaysia [31], 9.8% feared that
PrEP would not work. Participants in qualitative studies in
Malaysia and India thought that although PrEP has been
shown to be effective in other high-income countries, it
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may not work well among local Asian MSM [32,52]. These
concerns were particularly brought to the fore given that
condoms were considered an alternative to PrEP by parti-
cipants in Malaysia. In Thailand, 35% of MSM believed
condoms were more effective than PrEP and therefore
would prefer to use the former [43].
In Peru and Kenya, participants emphasized that being
confident that PrEP is effective would motivate them to use
it. A participant in a Peruvian study said: “It would have to
be 100% effective” for him to use it [50], while in Kenya, a
focus group participant stressed that: “If I am sure it is
going to work, it will motivate me to take it.” [51].
However, 44.4% of participants in Taiwan [40] were willing
to take PrEP even if it was not 100% effective, which may
be related to the high likelihood of this study’s participants
to use condoms: the majority of men willing to use PrEP
indicated that they would maintain their condom use if
taking PrEP (73.6% vs. 23.6%; p < 0.001).
Preference for condoms
Concerns of effectiveness aside, findings suggested that
some participants regarded condoms as mutually exclusive,
and in this context, some MSM preferred condoms instead
of PrEP. In Malaysia [31], 11.4% of the participants who
reported not willing to use PrEP, identified the fact that
they always use a condom as a reason why they would not
need PrEP. In another Malaysian study [32], the physical
barrier of condom was preferred to use drugs which cannot
be seen and felt. One participant in this study remarked
that “there is a physical barrier that we can see in the
condom, rather than drugs.” In the Chinese study by Ding
et al. [36], participants reporting condom use during their
last anal sex with a man were significantly less willing to
use PrEP (AOR:0.68; 95% CI = 0.47–0.97, p = 0.034), which
may be linked to preference or risk perception.
This finding is particularly relevant given that MSM par-
ticipants in a Peruvian study [50], and one key informant in
an Indian study [52] were concerned that availability of
PrEP could reduce the use of condoms. One Peruvian
MSM participant, in response to a question about the
impact of PrEP, responded by saying that:
‘If you tell someone, “Look, take this pill and it will
prevent you from getting HIV,” I can assure you
that the next day, that person won’t use a condom
anymore.’
In a typical response regarding how to deal with this situa-
tion, participants in this Peruvian study suggested the need
for PrEP education to clarify if and how condoms should be
used in combination with PrEP, while emphasizing that PrEP
may not be 100% effective:
‘There should be a lot of information and say that
it is something additional to condoms and which is
going to give you some extra protection. If you tell
them that [PrEP] is 100% protective, they won’t use
[a condom] anymore.’
PrEP as a back-up plan
In Malaysia and India, there were participants who consid-
ered PrEP a complementary strategy in the context of
inconsistent condom use [52], or as a “second layer” of
protection in case condoms fail [32], or on occasions where
condom use was intended, but did not occur.
Potential resistance
One study reported concerns regarding the potential emer-
gence of ARV drug resistance. In a Chinese study [49], 21.7%
of participants expressed worries about ARV drug resistance
from PrEP, and saw resistance as an important factor to
consider while making decision whether to use PrEP.
Need for frequent monitoring and testing
Data from two studies reported the influence that the need
for frequent clinical monitoring and HIV testing could have on
individual willingness to use PrEP. In a multi-country study by
Eisingerich et al. [34], 55.0–88.0% were willing to use PrEP
with regular HIV testing. However, a study in Thailand [43]
indicated that overall, 28.0% of participants “didn’t want to
see a doctor every three months.” In Kenya [51], a minority of
participants also reported they would not want to return for
the required regular HIV testing, and one asserted that: “I will
visit the clinic to see if it will work, but after that, if it works, I
will rarely visit clinic, will just continue to use the medicine.”
Social factors
A range of factors in family and community domains were
reported to influence willingness to use PrEP.
HIV stigma
Because similar ARV drugs are used for PrEP as for treatment
of those infectedwith HIV, HIV-related stigma, specifically fear
of being mistakenly identified as a person with HIV [49,51], or
being identified as a person at risk of HIV [52,53] were identi-
fied as potential barriers of the future use of PrEP. Fear of
being identified as a person at risk of HIV was particularly
prevalent in India and China [52,53]. In one Chinese study
[49], 20.1% of MSM participants expressed worries about
using PrEP for fear of being “treated as an AIDS patient by
people.” Participants from Kenya suggested that using differ-
ent packaging from that used for ARV drugs for treatment of
HIV could reduce potential perceived HIV-related stigma [51].
Participants stressed that unless that was done, peers would
begin “classifying you as HIV positive.”
Stigmatization of PrEP and homosexual orientation
Apart from HIV-related stigma, three studies documented
potential stigma that can be associated with users of PrEP,
based on their assumed sexual orientation and behaviours.
In some studies, this phenomenon was referred as “PrEP
stigma” [35]. In a Malaysian study [32], some participants
felt that being on PrEP would be perceived by peers as
having a direct association with riskier behaviours such as
barebacking or using drugs during sex. In this study [32],
PrEP was linked to sex work by a participant who suggested
that PrEP use is “a money boy or go-go boy who is not in a
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position to negotiate safe sex.” In a Peruvian study [50],
MSM were wary of accessing PrEP in neighbourhood drug-
stores because they were “afraid of being identified as a
person who has [homo] sexual relationships.” In an Indian
qualitative study [52], beliefs that potential PrEP users were
high-risk individuals – promiscuous, sex workers, or have
multiple sex partners – was also reported as a potential
barrier to the uptake, due to anticipated stigma. In the
multi-country study by Ayala et al. [35], PrEP stigma was
negatively correlated with willingness to use it (β: −0.51;
95% CI = − 0.55 to −0.48, p < 0.001). These themes were
further advanced by a study in Thailand [33] that explored
the extent to which participants may feel embarrassed to
use PrEP, and found that 2.7% thought that taking PrEP
would potentially be “very embarrassing” and 5.8% “fairly
embarrassing.” In another Malaysian study [31], of the
participants who reported not willing to use PrEP, 5.8%
identified concerns about “what other people might think
of me” as a reason they would not use it.
Importance of partner, peer, and family support
Data from three studies suggested that influence, reaction,
or support from partners, peers and family could either be a
barrier or facilitator of PrEP use. In an Indian qualitative
study, the possibility of covert use of PrEP not requiring
partner approval was seen as a facilitating factor [52], sug-
gesting that some participants fear that their partners may
not be supportive. In a Chinese study [49], 14.5% of partici-
pants were worried about being refused sex by male part-
ners after using PrEP. In a multi-country study by Eisingerich
et al. [34], proportions of participants who would definitely
want their partner or partners to know if they were taking
PrEP were 70.0% among Indian, 52.0% among Peruvian, and
68.0% among South African participants. The importance of
peer influence was reported in China [48], where the propor-
tion willing to use PrEP increased from 64.0% to 77.0% if it
were free and also used by people known to the participants.
In Peru, the influence of peers was also documented [50]. In
a typical response characterizing other participants in the
study, one MSM reported that he would consider using PrEP
because “most of my friends were going to use it.” In this
Peruvian study [50], participants also expressed concern
regarding potential judgment from family if he was discov-
ered to be using PrEP:
‘I think that there would be some kind of rejection
from my family. . .they would think I am a promis-
cuous person.’
Structural factors
Cost of PrEP
Cost emerged as an important barrier to use of PrEP in
India, China, Kenya, Malaysia, Peru, Myanmar and Taiwan.
In India, participants anticipated drugs for PrEP to be highly
priced [52]. In China, 26.3% of participants expressed worry
about not being able to afford PrEP [49]. In Malaysia,
participants suggested that PrEP should be free of charge
at the point of access, or at a reduced cost, with the
government covering the cost [31,32]. In this context [31],
8.8% of the participants who were not willing to use PrEP
identified failure to afford it as the reason they would not
use it. In the Chinese study by Zhang et al. [48], the
proportion of MSM willing to use PrEP increased from
64.0% to 71.0% if it were completely free. In Myanmar,
willingness to use PrEP was 62% as long as participants
were not required to pay for it [37]. In Peru [50], however,
participants noted that if initially provided free of charge,
users should not be required to pay for it later as that
approach may reduce its utilization:
‘If free. . .they would get used to have it for free all
the time, and when it is unavailable, they just
won’t buy it.’
In Kenya, participants in focus group discussions suggested
that they would be motivated to use PrEP if it would be
available at a subsidized cost to a price comparable to that
of condoms [51]. Subsidized or free distribution of PrEP
through community-based organizations was also identified
as a potential facilitator of PrEP uptake among lower socio-
economic status MSM in India [52].
In most studies, having to pay for PrEP reduced but did
not eliminate willingness to use it. In Malaysia, about one-
third (35.6%) of participants were willing to pay out-of-
pocket for PrEP, and of these, 88% were willing to pay for
it if it cost less than RM200 (USD50) per month [31]. In
Taiwan, 56.0% participants initially expressed willingness to
use PrEP, but the percentage fell to 23.0% when partici-
pants were asked if they were willing to pay an estimated
USD340 monthly for it [40]. Similarly, in Brazil [39], 75.8%
of all participants reported that they would use PrEP even if
they had to pay for it, a reduction from an overall rate of
82.1%. In a multi-country study by Eisingerich et al. [34],
39.0–88.0% of participants were willing to use PrEP despite
having to pay for it. In a Thai study [43], 65.0% of those
willing to use PrEP (36.0%) indicated they would be willing
to pay for it. In another Thai study [33], 58.8% were
“definitely” while 35.0% were “probably” willing to use
PrEP despite having to pay 500 Baht (USD15) a month for it.
Access to and attitudes of health professionals
Data from one study in Vietnam [41] indicated that previous
contact with peer health educators doubled the odds of
willingness to use PrEP (AOR: 2.28; 95% CI = 1.25–4.14,
p < 0.05). Findings from Peru emphasized the importance
of health-care professionals, especially in relation to stigma-
tizing attitudes [50]. In the multi-country study by Ayala et al.
[35], participants were concerned about potential stigmatiz-
ing attitudes from health providers. However, findings from
this study suggested that having experienced stigma was
positively correlated with higher willingness to use of PrEP
(β: 0.12; 95% CI = 0.02–0.23, p = 0.021), probably because
PrEP could be used without having to access healthcare
facilities for other HIV prevention services.
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Confidentiality and data protection
The fear of poor confidentiality and lack of data protection
of MSM’s identity, especially in public health facilities, was
identified as a barrier in a study in Malaysia [32], where a
participant remarked that “in the government clinic you
have to register, it has to be on record, so that’s not
discreet.” This was particularly important for participants
given stigma and cultural and religious sentiments towards
MSM in the Malaysian context.
Quality assurance of PrEP
A belief that pharmacies may distribute fake PrEP under-
mined trust in the quality and potency of PrEP in India [52].
Although quality can affect the effectiveness of PrEP in any
context, these concerns seemed unique to pharmaceutical
quality control systems in India, as they were absent in
other studies.
Ways to access PrEP
Several studies explored ways in which MSM wanted to
access PrEP. Venues identified for potential PrEP access
included public health facilities [31,50,52], community-
based organizations (CBOs) [31,32,52], pharmacies [31,50],
and online websites [31]. Participants’ preferences were
not consistent, but depended on their perceptions related
to stigma, data protection, and costs at each of these
venues. In India [52], some participants preferred PrEP to
be provided through government facilities as they were
concerned that if dispensed through CBOs, other MSM
might find out and label them as promiscuous. In contrast,
government facilities were viewed as likely to compromise
data confidentiality in Malaysia, and CBOs were preferred
instead [32]. MSM in Peru [50] preferred PrEP being avail-
able in healthcare centres as opposed to pharmacies, citing
higher costs. Overall, these findings suggest that increasing
ways through which PrEP can be provided could increase its
uptake, as it would cater for the needs and preferences of
different MSM.
Discussion
This review set out to determine the awareness of and
willingness to use PrEP among MSM in low-and middle-
income countries. The review found that although it varies,
awareness of PrEP among MSM in low-and middle-income
countries is generally low, ranging from 0% to 72%, with a
pooled awareness of 29.7% (95% CI: 16.9–44.3) across all
studies. In contrast, willingness to use PrEP is relatively
high, ranging from 19% to 96%, with a pooled estimate of
64.4% (95% CI: 53.3–74.8). These results suggest that once
MSM become aware of PrEP, the majority are willing to
use it.
The finding of low PrEP awareness echoes that from a
previous review by Young and McDaid which showed that
MSM, sex workers, injecting drug users, and serodiscordant
participants in PrEP studies that were not part of larger
PrEP clinical research trials had limited knowledge of PrEP,
ranging from 11.0 % to 23.0 % [15]. Our review suggests
that actual awareness of PrEP may be lower than reported
in previous studies, given that participants’ understanding
of PrEP was not accurate in two studies [45,52]. This has
also been observed in studies from high-income countries.
In a US study [56] in which 62.0 % of participants had
claimed to have heard of PrEP, one-quarter were found to
have mistook PEP for PrEP.
Compared to studies in high-income settings, this review
suggests that willingness to use PrEP is relatively higher
among MSM in low-and middle-income countries. A 2012
study reported that only 28.2% of Australian MSM were
willing to use PrEP [57]. More recently, in Europe, propor-
tions of MSM willing to use PrEP have ranged from 47.8% to
54.3% in Scotland [58,59], 57.0% in Portugal [60] and 57.6 %
in Spain [61]. Recent Canadian studies reported willingness
to use PrEP of 55.0% [62,63]. In the US where the majority of
studies on PrEP have been conducted, willingness to use
PrEP has ranged from 46.1% to 71.0% [64–69].
Nevertheless, the reported willingness to use could even-
tually change when PrEP is actually offered as was the case in
one Chinese study [36] included in this review, whereby 20.5%
changed their minds when PrEP was subsequently offered.
The accuracy with which willingness to use predicts actual
acceptance is difficult to determine as it could change based
on individual circumstances as well as the setting within which
PrEP is provided. For instance, the majority of MSM in open-
label extensions of RCTs show willingness to enrol, and most
go on to use it [6,70–72], although with sub-optimal adher-
ence [71,72]. However, contexts of open-label extensions and
preceding trials differ from regular programmes in terms of
patient preparedness, education and support, and may there-
fore positively bias its use [15]. More realistic observations
from 20 US cities suggested that although over half of MSM
reported willing to take PrEP, only 4% actually used it [68].
Therefore, understanding the relationship between willing-
ness to use and actual uptake of PrEP in “real-world” HIV
prevention programmes in LMIC should be prioritized in
future PrEP implementation research.
Besides the overall willingness to use PrEP, our review
provides important information regarding barriers and
motivations of its use, in response to earlier calls to
increase understanding of the context within which PrEP
might be accessed and utilized [15]. In particular, this
review identified a range of individual, social and structural
factors that may influence the willingness to use PrEP. In
the individual domain, poor knowledge about PrEP, and
doubts about its effectiveness, were common potential
barriers, alongside fear of side effects, low-risk perception
among those at high risk, and inconvenience of having to
ingest medicines daily. In addition, participants tended to
view PrEP as a competing intervention against condoms.
These findings suggest that PrEP education and informa-
tion should be prioritized, including provision of accurate
information about the role of PrEP within combination HIV
prevention as recommended by WHO [4,5]. Differentiating
PrEP from PEP to potential adopters in LMIC would be
important, at least initially. Studies from high-income set-
tings such as Spain [61] have demonstrated the importance
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of awareness in determining willingness to use PrEP. Beyond
just hearing about PrEP, the way in which PrEP information is
provided to MSM, and how well they were able to under-
stand it, could influence their levels of willingness to use it. In
this review, some studies provided opportunities for one-to-
one discussions on PrEP, others provided this information
through anonymous survey, and while each has its merits,
they could influence willingness differently. Our review also
found that peers, healthcare providers, print media, and
internet websites are all useful sources of information
about PrEP for MSM. Provision of PrEP and HIV prevention
information through online and mobile dating applications
could be particularly effective in reaching MSM at higher risk
of HIV infection. This is particularly relevant given that high-
risk MSM in at least two studies did not always view them-
selves to be at risk of HIV [32,48].
HIV risk perception and behaviours have been found to
be important determining PrEP utilization in high-income
settings [12,62,73]. Four studies in this review [36,37,40,48]
found that MSM who had more anal or casual sexual
partners, those who had received PEP, and those with a
history of STIs were more willing to use PrEP, possibly
because they had stronger perceptions of risk. A recent
review found that PrEP use was associated with STIs
among MSM [74], which underscores the need for compre-
hensive prevention package [75]. However in our review, it
was notable that willingness to use PrEP was high among
some participants who were at low risk e.g. those who had
one regular partner or no casual partners in Myanmar [37],
which could be due to incorrect risk perception, or bias to
use HIV prevention among MSM who were already practis-
ing safe sex behaviours. Disconnect between objective and
subjective HIV risk has also been identified in MSM from
high-income settings [76]. To address these uncertainties of
risk and optimize PrEP utilization among those at substan-
tial risk of HIV as recommended by WHO [4,5], additional
research and programmatic tools should be devised to
assist individuals have a better self-awareness of their HIV
risk.
In addition, it is critical to continue exploring ways in
which convenient and safe PrEP can be delivered to
sidestep concerns regarding the need for frequent inges-
tion of drugs. Concerns regarding long-term adherence
have also been reported in the UK as a deterrent of
potential PrEP use [12]. In our review, injectable or less
frequent dosage schedules were more preferable to oral
pills [33,34,43,50]. However, user preferences are highly
contextual. In the US, a study reported that MSM pre-
ferred daily oral pills and non-visible implants over injec-
tions or visible implants, citing convenience, duration of
protection, and privacy [77]. A recent trial found that
PrEP adherence was higher in daily, compared to less
frequent time- or event-driven dosing regimens [78],
although participants in this trial were simply randomized
to these arms and didn’t have a choice. While conform-
ing to user preferences is essential for a tailored PrEP
programme, method of delivery may have an effect on
cost, adherence, PrEP coverage per sex-act, and ulti-
mately, “real-world” effectiveness.
A range of other individual demographic factors including
educational level, age, and residency were noted to influence
willingness to use PrEP. However, these were not universal
nor were their impacts consistent across all studies. However,
there is a need to tailor provision of PrEP to specific MSMwho
are particularly at risk of HIV based on their age groups,
migration and socio-economic status and other characteris-
tics, as part of effectively tailored combination of HIV preven-
tion interventions. For instance, studies from the USA suggest
that PrEP can be feasibly provided to young MSM [79].
Within social and interpersonal domains, stigma was the
single most commonly encountered factor. Our review
found that MSM anticipate stigma from peers, partners,
family as well as healthcare providers and that this stigma
may be either related to HIV [49,51–53], or behaviours that
may warrant the use of PrEP [80,81], such as sex work [32]
and homosexual sex [31–33,35,50,52]. These findings sug-
gest that it is essential to integrate strategies to mitigate
stigma related to sexual orientation as well as HIV within
PrEP programming. Chakrapani et al. suggest that commu-
nity engagement may facilitate broad acceptability and
challenge stigma around PrEP [52]. Unfortunately, existing
evidence suggests that although community mobilization
and collectivization interventions can indeed mitigate
stigma [82], it is difficult to eliminate it unless these social
interventions are combined with structural interventions
and this may include decriminalization of same-sex rela-
tions in some settings.
Stigmatization in health facilities is particularly detrimen-
tal as it can prevent health seeking for other services,
suggesting that competency and skill-based training, sensi-
tization, and performance improvement to enable provision
of friendly HIV prevention services will be required, as
argued by others [81]. The extent of partner, peer, and
family support was a significant factor affecting willingness
to use PrEP, especially in the context of stigma. Therefore,
PrEP programmes will need to ensure that consideration is
given about how partners and peers of MSM can be lever-
aged on to facilitate, rather than hinder, access and utiliza-
tion of PrEP.
Key structural factors included perceived staff attitudes,
a lack of quality assurance, a lack of data protection and
confidentiality, and cost [31,32,37,40,50,52]. Apart from
addressing stigma and general competency to provide
MSM with PrEP among healthcare providers in LMIC –
which have been noted by others [83,84] – our results
suggest that strengthening health systems so as to assure
universal provision of high-quality PrEP, while protecting
the identities of MSM, will be critical. Strengthening drug
regulation in middle-income countries has also been high-
lighted as essential by other authors [85]. In this review,
cost was a common determinant of willingness to use PrEP.
Although several studies suggested thresholds at which
MSM would be willing to pay for PrEP, the studies were
conducted in diverse LMICs and socio-economic back-
grounds, making it difficult to generalize thresholds.
Furthermore, most studies were conducted in cities, and
mostly in middle-, rather than low-income countries.
Nevertheless several studies [31,33,34,39,40,43,48,51]
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suggested that there were MSM in Kenya, Malaysia, Brazil,
Taiwan, Thailand, Peru, India, and South Africa who might
be motivated to use PrEP, despite having to pay full or
subsidized price for it.
Strengths and limitations of this review
Our findings build on those of previous reviews conducted by
Holt, Young, and McDaid [14,15] which focused on general
acceptability of ARV-based prevention. A unique strength of
our review is the focus on, and inclusion of, a substantially
greater number of studies from low- and middle-income
countries. Most studies in this review were Asian with rela-
tively limited data from low- and middle-income countries in
Eastern Europe, West and North Africa, or the Caribbean
counties. However, inclusion of multi-country studies
[34,35] strengthened the generalizability of this review to
LMIC settings. In addition, the focus of the review on aware-
ness and willingness to use realistically reflects the current
early stages of PrEP introduction in LMIC, as it excludes
acceptability which is more suited for high-income settings
where PrEP for MSM is more widely available.
The range of individual, social, and structural factors
identified in this study are likely to remain relevant even
after PrEP among MSM becomes available. Sub-optimal
uptake and retention in PrEP has been reported in the US
outside of open-label extensions [86–88] often due to simi-
lar issues identified in this review such as poor awareness
levels, cost, low risk perception, need for daily intake, and
fear of potential side effects [87–89]. Addressing these
barriers in low- and middle-income countries is particularly
relevant given that implementation of PrEP in LMIC has
lagged behind compared to high-income countries [15,16].
Rapidly scaling up access and utilization of PrEP will require
mitigating barriers while accentuating facilitators of its
potential uptake identified in this review.
We did not conduct sub-group analyses. Geographic and
socio-demographic comparisons could provide insights into
contextual determinants of awareness or willingness to use
PrEP. As noted previously, reported proportions were highly
heterogeneous. The diversity of scales and measures used
to estimate willingness to use PrEP in the included studies
may have affected the precision of our estimates, since the
observed proportions might not be entirely attributed to
sampling error, and other factors such as differences in
MSM participants and their settings could also contribute.
For this reason, we used random-effects model rather than
fixed effects model, which provides more conservative esti-
mates e.g. wider 95% CIs, while assuming that the measure-
ment of the parameter of interest may not be entirely
identical across studies [29]. Nevertheless, our overall find-
ings are consistent with previous reviews which observed
high rates of willingness to use PrEP, regardless of the type
of scales used in individual studies [14,15].
Although all the included studies provided sufficient infor-
mation to enable assessment of risk of bias, this was found
to be relatively high, mainly due to study designs and neces-
sary reliance on self-reported sexual behaviour data. Survey
and interview questions related to sensitive, criminalized or
taboo sexual activities often generate inaccurate estimates
due to social desirability bias [90]. The perception of PrEP
varied both between and within studies, with its use being
seen as responsible by some participants [50] and as indica-
tive of risky sexual behaviour by others [32,33,50,52]. Thus,
it is not possible to state with certainty the net effect of
social desirability bias on our overall findings.
Findings of this review are not generalizable beyond oral
PrEP which was the focus herein; awareness and willingness
to use other forms of PrEP might be different. Because PrEP
is frequently explored in the context of expanding combi-
nation prevention options for populations at highest risk
[4,85,91], awareness and willingness to use it could vary
based on contact with PrEP-related research and demon-
stration projects [81,92]. Although several databases were
searched, some studies may have been missed. Relevant
information reported in conference abstracts and non-peer
reviewed literature may have been missed as the review
only considered peer-reviewed publications to minimize
bias. While language limitations were not applied, no stu-
dies published in languages other than English and Chinese
were found. Publishing bias may still exist. Nevertheless,
this review utilized standard approaches of conducting [30]
and reporting systematic reviews [17] to minimize bias.
Conclusions
Over the last few years, RCTs have demonstrated the effec-
tiveness of oral PrEP in reducing the risk of HIV acquisition
among MSM [9,10], demonstration projects are increasingly
being implemented [71,72,81] and the WHO has endorsed
the use of PrEP by MSM and other populations at substan-
tial risk of HIV [4,5]. Although PrEP policies are starting to
be put into place in counties such as Malaysia, Kenya, and
South Africa, actual implementation of PrEP in low- and
middle-income countries has been relatively limited
[15,16]. In addition, criminalization of same sex relations
may limit uptake of prevention services among MSM [93].
Programmes intended to introduce or scale-up usage of
PrEP need to be based on context-specific evidence, such
as potential demand and user preferences, supported by
enabling legal and policy framework environments. This
review contributes to this evidence base by demonstrating
that despite currently low awareness of PrEP, MSM in low-
and middle-income countries are willing to use it once they
become aware of it and they should be appropriately sup-
ported to deal with a range of individual, social, and struc-
tural barriers.
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